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”As we enter the era of Big Data, with information and processing power 
increasing at exponential rates, it may be time to develop a healthier attitude 
towards computers and what they might accomplish for us. Technology is 
benificial as a labor-saving device, but we should not expect our machines to 
do our thinking for us.” 
 
 
“The numbers have no way of speaking for themselves. We speak for them. 
We imbue them with meaning.” 
 
 
From “The Signal and the Noise:  
why so many predictions fail - but some don’t” 
Nate Silver 
 
 
 
 
 
 
 
 
  
ABSTRACT 
“Hur många barn får jag när jag blir stor?”  
Controlling fertility, or rather infertility, is a common problem for couples nowadays 
where approximately 10% experience infertility. This thesis focuses on the rare 
conditions leading to infertility in which the gonads have either failed to develop 
properly, or prematurely lost their function. The overall aim of this thesis was to 
identify and study candidate genes in gonadal disorders of sex development (DSD) and 
primary ovarian insufficiency (POI) to achieve a better understanding of the underlying 
molecular mechanisms and to improve available diagnostic tools and genetic 
counseling for affected patients and family members. 
The process of sex determination is sensitive to gene dosage, and genes affecting 
gonadal development are located on sex chromosomes and autosomes. Attempting to 
identify new candidate regions for testicular development, nine patients with 46,XY 
complete gonadal dysgenesis were investigated with a customized 1M array-CGH 
(comparative genomic hybridization) platform with whole-genome coverage and probe 
enrichment targeting 78 genes involved in DSD. Aberrations affecting SUPT3H and 
C2ORF80 were identified and characterized in two affected sisters. Sequence analysis 
of these genes in all patients revealed no additional mutations. PIP5K1B and PRKACG 
were also identified as candidate genes in another patient. All four genes are expressed 
in testicular tissues, and one is shown to cause gonadal DSD in mice (Paper I). 
Based on the report of one patient with 46,XY ovarian DSD due to CBX2 mutations 
and the corresponding knock out mouse model, we considered CBX2 as a candidate 
gene for 46,XY/46,XX gonadal DSD and POI. By sequencing and MLPA a cohort of 
47 patients with gonadal DSD or POI was investigated for sequence alterations and 
copy number changes in CBX2. No causative mutation was detected. Our study does 
therefore not support CBX2 mutations as a common cause of gonadal DSD (Paper II). 
DNA samples from 26 patients with POI were analyzed by our customized array-CGH 
platform to identify novel candidate genes in POI. Eleven unique copy number changes 
were identified in a total of 13 patients. We identified the first mutation affecting the 
regulatory region of GDF9, a 475bp duplication containing three NOBOX binding 
elements and a regulatory E-box. In addition, we found the second DNAH6 deletion, 
corroborating its potential role in causing in POI. Also TSPYL6, SMARCC1, CSPG5, 
SH3GL3 and ZFR2 were identified as candidate genes in POI (Paper III). 
PSMC3IP mutations have been described causing autosomal recessive POI in a 
consanguineous family with several affected members. We are the first to have 
investigated the PSMC3IP gene in a group of unrelated patients with POI. No mutation 
was detected and we therefore conclude that PSMC3IP mutations are not a common 
cause of POI in a Swedish patient cohort (Paper IV). 
In conclusion, there is accumulating evidence that gonadal DSD and POI are highly 
genetically heterogeneous. We recommend that the genetic investigation of patients 
with gonadal DSD should be centralized to a specialized DSD unit. Patients with POI 
should be handled by subspecialists within reproductive endocrinology and clinical 
genetic investigation can require genetic counseling. A suggested clinical investigation 
procedure for POI is presented. Ideally, genetic investigation of patients with gonadal 
DSD or POI should include investigation for gene dosage aberrations as well 
sequencing of several candidate genes. 
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 INTRODUCTION 
“Hur många barn får jag när jag blir stor?” 
A popular children’s game at daycare when I was a child, was to grab some gravel, and 
throw it in the air while saying “How many children will I have when I grow up?”. The 
number of small rocks you would catch was how many children you would have as an 
adult. Sometimes “fate” would give you ten, and sometimes none. You could always 
try to catch the desired number, but most often, you got what you got. As silly as this 
game would seem growing up, controlling your fertility, or rather the unwanted 
infertility, is a common problem for couples today. Approximately 10% of all couples 
trying to conceive will experience infertility [1]. There are many different factors that 
can cause infertility, both in men and women. This thesis will only focus on the rare 
conditions leading to infertility in which the gonads have either failed to develop 
properly, or prematurely lost their function. To study these patients, and understand the 
investigations undertaken, an understanding of the normal process of sex development 
is necessary.  
SEX DEVELOPMENT 
Human sex development is a continuous process, starting at fertilization, and 
continuing through puberty when the adult sex appearance is acquired along with 
fertility potential. This process is governed by genetic and hormonal factors.  
At fertilization, the genetic sex is determined by the sex chromosome complement. 
Normally, men have one X and one Y chromosome (46,XY), and women two X 
chromosomes (46,XX). The next step is called sex determination, with the 
differentiation of the bipotential gonads into either ovaries or testes, followed by sex 
differentiation, the differentiation of the internal and external genitalia into either a 
male or female phenotype.  
Sex determination  
During embryonic development, the gonads are initially formed as bipotential and can 
develop into either ovaries or testes. The gonadal anlagen appear at 32 days post 
conception (pc), arising from the mesoderm. The anlagen consist of three different 
bipotential somatic cell lineages, the supporting, steroidogenic and stromal cells. By the 
5
th
 week pc, the primordial germ cells, migrating from the yolk sac, start to colonize the 
gonads [2]. At week 6-8, sex determination occurs, when the somatic cells and  
Introduction 
2 
Table 1. Gonadal cell lineages. 
Testis Bipotential gonad Ovary 
Spermatogonia Germ cells Oogonia 
Sertoli cells Supporting cells Granulosa cells* 
Leydig cells Steroidogenic cells Theca cells 
Peritubular cells Stromal cells Stromal cells 
*Granulosa cells also have a steroidogenic function with progesterone production and aromatase 
conversion of androgens to estradiol. 
 
 
primordial germ cells of the gonad differentiate into ovarian or testicular cell types 
(table 1) depending on the predominant activation of the SRY/SOX9 or RSPO1/WNT4 
signaling pathway, respectively (figure 1) [3]. 
Testes 
The differentiation towards testes starts around week 6 pc. The SRY gene, located on 
the male Y chromosome, initiates the differentiation towards testicular development by 
promoting SOX9 expression in pre-Sertoli cells [4, 5]. A positive feed-back loop 
stabilizes SOX9 expression, while WNT4 expression is suppressed [6]. The germ cells 
increase rapidly by mitosis and do not enter meiosis, but lie resting until puberty.The 
germ cells are nursed by Sertoli cells that express differentiation factors, paracrine 
signals and Anti Müllerian Hormone (AMH) necessary for male sex differentiation. 
The expression of DHH and FGF9 by Sertoli cells is essential for differentiation of 
Leydig cells, which in turn express NR5A1 necessary for Sertoli cell AMH production 
[7]. The Leydig cells are the steroidogenic cells of the testes producing androgens from 
the 8
th
 week pc. The development of the somatic cell lineages to form the 
morphological testicle is not dependent on the presence of germ cells, but occurs 
independently of these [2].  
Ovaries 
Around 7 weeks pc, the differentiation towards ovaries starts in 46,XX embryos. It is 
not, as previously believed, a passive process in the absence of SRY, but an active, 
genetically determined process where RSPO1 and WNT4 upregulation is important [8]. 
However, no “ovary determining factor” comparable to SRY has so far been identified. 
 
Introduction 
  3 
Figure 1.Sex determination.  
 
Names in italics symbolize genes. Name in smaller normal font represent protein. Cell type specific 
expression is indicated by circle. Positive interaction is indicated by arrow, negative by T-sign. Positive 
interaction by hormone signaling is indicated by dashed line.  
 
 
The ovarian development of follicle organization is dependent on correct interaction of 
germ cells and granulosa cells [2, 9]. The interaction process is not clearly understood, 
but close cell organization and paracrine signaling are important. Germ cell specific 
expression of FIGLA and NOBOX [9], along with selective FOXL2 expression in 
developing granulosa cells, has been shown [2]. NR5A1 is expressed by both granulosa 
and theca cells, and is a major regulator for the steroidogenesis except for corpus 
luteum progesterone production [10].  
The germ cells proliferate by mitotic division, and before birth, enter meiosis, where 
they arrest in the diplotene stage. Around week 12 pc the germ cells are surrounded by 
somatic granulosa-cell precursors, and these develop to form primordial follicles. 
During gestation, they develop into primary and later secondary follicles. However, 
many undergo programmed cell death, and at birth approximately 2 million follicles 
remain [2]. 
Sex differentiation 
The differentiation of the internal and external genitalia into male or female phenotype 
is termed sex differentiation. 
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Internal genitalia 
Both the Wolffian ducts, that give rise to the male internal genitalia, and the Müllerian 
ducts, that establish the female internal genitalia, are formed during early gestation. 
AMH production by Sertoli cells in the testis causes regression of the Müllerian ducts. 
Androgens, produced by the Leydig cells around gestational week 8, are important for 
the development of the Wolffian ducts into the epididymis, ductus deferens and seminal 
vesicles [2, 11]. In the absence of AMH, the Müllerian ducts persist and form the 
uterus, fallopian tubes and the upper part of the vagina. In the absence of androgens, the 
Wolffian ducts regress and form the suspensory ligament of the ovary and the Garner’s 
ducts. AMH is also produced in low levels by primordial follicles, but at a later stage 
and this does not affect development of the Müllerian ducts [2].  
External genitalia 
The bipotential external genitalia start differentiating at gestational week 8 into a male 
phenotype in response to androgens and dihydrotestosterone (DHT) in particular. In the 
absence of androgen action, due to failure to respond to or synthesize androgens 
(testosterone and/or DHT), the external genitalia develop in a female pattern. [12] 
Fertility potential 
At puberty the normal sex development culminates with the activation of the gonads by 
the pituitary-hypothalamic-gonadal hormone axis. The surge of FSH (follicle 
stimulating hormone) and LH (luteinizing hormone) from the pituitary glands in 
response to gonadotropin releasing hormone (GnRH) causes the supporting cells of the 
gonads to produce male and female sex steroids, and activate the germ cells. In men the 
spermatogenesis is initiated, and in women the menstrual cycle starts with menarche. 
Womens’ fertility peaks between the age of 25 and 30 after which it steadily declines, 
along with decreasing follicle quality and quantity. The loss of fertility often precedes 
the loss of menstruation. The overall international median age of natural menopause is 
estimated to 50 years of age with a normal distribution range between 40 and 60 years 
and a standard deviation (SD) estimate of +/- 4 years [13, 14]. 
Gender  
Gender can be considered as a part of the developmental process. It comprises gender 
identity, how one perceives one self, and gender role, how one is perceived by 
others/society. Sexual behavior and orientation are other components of the overall 
sexual identity of an individual. These issues will not be discussed in this thesis.  
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DISORDERS OF GONADAL DEVELOPMENT 
Impaired sex development can cause Disorders of Sex Development (DSD), defined as 
“congenital conditions where development of chromosomal, gonadal or anatomical sex 
is atypical” [15]. DSD can be categorized into chromosomal DSD, caused by 
chromosomal aberrations including conditions with mixed and chimeric DSD, gonadal 
DSD, comprising disorders of gonad development and sex determination, and DSD 
caused by disorders of sex steroid synthesis and action. A revised nomenclature has 
been implemented since 2006 (table 2) [15]. This thesis focuses on gonadal DSD.  
 
Table 2. DSD classification and terminology. 
Chromosomal DSD 46,XY DSD 46,XX DSD 
A. 45,X 
Turner syndrome and variants 
A. Gonadal DSD A. Gonadal DSD 
B. 47,XXY 
Klinefelter syndrome and 
variants 
1. Complete gonadal 
    dysgenesis (GD) 
2. Partial GD 
1. Gonadal dysgenesis  
    (GD)* 
C. 45,X/46,XY 
Mixed GD, ovotesticular DSD 
3. Gonadal regression 
4. Ovotesticular DSD 
 
2. Ovotesticular DSD 
D. 46,XX/46,XY 
Chimeric, ovotesticular DSD 
5. Ovarian DSD
a
 3. Testicular DSD 
 B. Disorders of androgen 
synthesis and action 
E.g. AIS, CAH, 5α-reductase 
deficiency, CYP11A1 
deficiency 
B. Disorders caused by 
androgen excess 
E.g. CAH, POR mutation 
 C. Other DSD 
E.g. hypospadias, persistent 
Müllerian duct syndrome 
C. Other DSD 
E.g. MURCS, MRKH  
* In this thesis 46,XX GD is discussed as primary amenorrhea in primary ovarian insufficiency (POI)
  
a
 Only one patient reported so far. 
DSD, Disorders of sex development; AIS, androgen insensitivity syndrome; CAH, congenital adrenal 
hyperplasia; MURCS, Müllerian duct aplasia, unilateral renal agenesis and cervicothoracic somite 
anomalies; MRKH, Mayer-Rokitansky-Küster-Hauser syndrome.  
 
Introduction 
6 
Complete 46,XY Gonadal Dysgenesis  
One form of gonadal DSD is gonadal dysgenesis (GD) where the gonads have failed to 
differentiate. In complete GD, only streak gonads are present. Despite a 46,XY 
karyotype, as there are no Sertoli or Leydig cells secreting AMH and androgens in the 
developing embryo, the internal and external genitalia develop along the female 
pathway. These girls are often diagnosed in their late teens when they have not 
achieved menarche and a 46,XY karyotype is discovered. Patients can also be 
diagnosed at birth if a girl is born where a prenatal test has shown a 46,XY karyotype.  
As these patients lack sex steroid producing gonads, hormonal substitution is necessary 
even though low levels of sex steroids are secreted from the adrenal glands. Sometimes, 
these levels are sufficient for development of secondary sexual characteristics such as 
breast development and genital hair. If not, puberty can be induced by transdermal low-
dose estrogen substitution. Often a combined oral contraceptive is used as replacement 
therapy post-puberty as the cyclic pattern of the oral contraceptives also induces 
menstruation, although ovulation will not occur. The patients can carry a pregnancy as 
they have a uterus, but the lack of germ cells makes egg donation the only available 
option for pregnancy.  
The dysgenetic gonads, residing in the abdomen in these 46,XY subjects are at high 
risk of malignant transformation into germ cell tumors. This is believed to be due to the 
presence of Y chromosome material, where specifically expression of the testis specific 
protein encoded by TSPY on Yp11.2 is an important marker for malignancy potential. 
Due to the risk of gonadoblastoma, prophylactic gonadectomy is strongly 
recommended [16-19].  
Other 46,XY gonadal DSD 
There are patients presenting with partial forms of 46,XY gonadal dysgenesis, 
classified as partial GD. Here the phenotype is dependent on the hormonal function of 
the differentiated testicular tissue, with varying degree of ambiguous external genital 
depending on androgen production levels. The fate of the internal ducts is dependent on 
extent of AMH secretion and androgen levels.  
In gonadal regression, one or both testicles are absent upon external and internal 
examination despite a most often normal male phenotype. The unilateral absence of a 
testis is estimated to be as prevalent as 1 per 1250 men [20].  
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A rare form of 46,XY gonadal DSD is ovotesticular DSD where both ovarian and 
testicular tissue is present in one or both gonads. As in partial GD, the clinical 
presentation will vary between patients depending on androgen and AMH production. 
The treatment is based on individual consideration.  
One patient has been described with 46,XY ovarian DSD. This was a girl presenting 
with a normal female phenotype at birth despite a prenatal 46,XY karyotype. 
Laparoscopy and histological examination at 4 years of age identified bilateral ovaries 
with normal ovarian tissue and the presence of primordial follicles. The ovarian 
function could not be determined as the girl was still prepubertal [21].  
There are syndromic forms of 46,XY gonadal DSD, such as campomelic dysplasia 
(MIM 114290) and Denys-Drash syndrome (MIM 194080). It can also be noted that 
CYP11A1, or cytochrome P450 side-chain cleavage (P450scc) enzyme mutations, 
categorized as a disorder of androgen synthesis and action, can present with a variable 
phenotype depending on mutation, from complete 46,XY GD to mild hypospadias. In 
these patients the manifestation is always accompanied by adrenal failure, with a later 
onset in milder phenotypes [22].  
A specific molecular diagnosis can be established in 20-50% of patients with 46,XY 
gonadal DSD, depending on group classifications [15].  
46,XX gonadal DSD 
Patients with a female chromosome complement can present with ovotesticular DSD 
and are managed clinically with individual consideration, as for patients with 46,XY 
ovotesticular DSD. The clinical presentation is variable with different degrees of 
ambiguous external genitalia, and the AMH and androgen levels influence the fate of 
the internal genitalia. 
Patients with 46,XX testicular DSD present with a male phenotype, testes and a male 
hormonal profile. The patients are azoospermic, and often diagnosed later in life during 
an infertility investigation. The phenotype of external genitalia can vary, with 
presentation range from ambiguous external genitalia to mild hypospadias.  
In 46,XX gonadal dysgenesis only streak gonads are present and patients present as 
normal girls, who do not reach menarche. However, as the ovarian follicle organization 
is dependent on functioning interaction between germ cells and granulosa cells, 
conditions with completely undifferentiated streak gonads cannot be distinguished from 
conditions with premature loss of germ cells. As the term gonadal dysgenesis makes a 
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mechanistic supposition, is not a suitable term to describe all 46,XX patients with the 
clinical presentation of primary amenorrhea. In addition, ovarian dysfunction can be 
seen as a continuous spectrum from a complete form of undifferentiated gonads to a 
partial defect with premature loss of ovarian function. Therefore, these patients will be 
discussed under the term primary ovarian insufficiency. The patients are further 
subdivided depending on the clinical presentation of primary or secondary amenorrhea.  
As POI is a very heterogeneous condition with variable presentation, it is not suitable to 
define it as a form of gonadal DSD. Instead, POI will be discussed separately, and the 
term POI with primary amenorrhea will replace 46,XX GD in this thesis. 
PRIMARY OVARIAN INSUFFICIENCY 
Ovarian dysfunction that occurs before the age of 40 is called primary ovarian 
insufficiency (POI), defined as prolonged amenorrhea accompanied by repeated serum 
FSH levels in the menopausal range [23, 24]. Elevated FSH levels with concurrent low 
estrogen levels is a status termed hypergonadotropic hypogonadism. The estimated 
general population incidence of POI is 1% [25]. 
POI can present with either primary (PA) or secondary amenorrhea (SA), where the 
latter has previously been termed premature ovarian failure (POF). However, as some 
remaining ovarian function can exist despite SA, the terms POF or premature 
menopause are considered misnomers. Approximately 5-10% of these women have 
delivered a child after receiving the diagnosis [23]. For patients with PA, fecundity has 
not been reported, but egg donation is an available option for achieving pregnancy. 
Hormonal substitution is necessary to avoid negative effects of lack of estrogens [26]. 
Often a combined oral contraceptive is used to mimic the normal cyclic hormonal 
pattern, but hormone replacement therapy regimes can also be followed. In the case of 
patients with PA who have not reached puberty, this can first be induced using low 
dose transdermal estrogen substitution. Substitution therapy is recommended up until 
the age of normal menopause, approximately 50 years of age. Clinical supervision of 
these patients is important to avoid negative effects of under-substitution such as 
osteoporosis, where repeated dual-energy X-ray absorptiometry exams are 
recommended. 
POI pathogenesis can be divided into follicle dysfunction and follicle depletion. 
Follicle depletion can be caused either by a small initial germ cell count, or a rapid 
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germ cell loss. External factors, such as surgery, irradiation, chemotherapy as well as 
autoimmune and metabolic disorders, can cause POI.  
Follicle dysfunction can be caused by enzyme defects, such as mutations in CYP17A1 
and CYP19A1. Also, autoimmunity with specific antibodies against the enzymes 
CYP11A1 (p450scc) CYP17A1 (17α-hydroxyalse) and CYP21A2 (21-hydroxylase) is 
associated with POI, most often in conjunction with autoimmune Addison’s disease 
[27, 28]. Thyroid disease is linked to ovarian function in women, and the presence of 
autoantibodies against TPO (thyroid peroxidase) is more frequent in women with POI 
[29].  
POI can be isolated, or associated to other symptoms, such as in Turner syndrome. 
Other examples include BPES (Blepharophimosis, ptosis and epicanthus inversus 
syndrome, MIM 110100) where women present with eyelid deformities and PA, and 
Perrault syndrome (MIM 233400) where female patients present with PA and 
progressive hearing loss. POI can also be a symptom in mitochondrial diseases, such as 
POLG mutations and PEOA1 (progressive external ophtalmoplegia with mitochondrial 
DNA deletions, MIM 157640). 
The absolute majority (90%) of all cases of isolated POI remain idiopathic [23]. 
However, there is a significant genetic component in POI and familial clusters are not 
uncommon [23, 30, 31].  
GENETICS  
The genes known to cause gonadal disorders of development and function have been 
identified by studying patients with DSD and different animal models. The sex 
determination process is similar for many mammals, and findings in one species can 
often be relevant for another. For instance, mouse Sry and Fshr mutation models are 
human phenocopies [7, 32]. In animal model studies, the mouse is the most frequently 
used. Other species are also used, for instance cattle and sheep for investigation of 
ovarian disorders. For these, interspecies differences in ovulation patterns must be 
taken into account. For instance, Bmp15 mutations do not affect phenotype in the 
polyovulatory mouse, but cause superovulation in the monoovulatory sheep [7].  
Genetic changes can cause gonadal DSD through different mechanisms. Point 
mutations of specific genes can cause loss of gene product function, loss of function 
mutations (LOF). If one allele is affected, a LOF mutation can cause gene 
haploinsufficiency, and if both alleles are affected, complete gene product loss. When 
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the phenotype shows autosomal dominant inheritance, haploinsufficiency is enough to 
cause the phenotype, whereas complete loss is necessary in autosomal recessive 
disease. A complete loss can occur when both alleles harbor the same mutation, where 
the patient is homozygous for the mutation. The patient can also carry two different 
mutations, called compound heterozygosity.  
If one allele is deleted, the patient is hemizygous. In an autosomal dominant condition, 
gene deletion of one allele is sufficient to cause the phenotype. If a deletion of one 
allele occurs together with a LOF mutation in the remaining allele, this causes a 
complete loss of gene product that can cause autosomal recessive disease. Entire gene 
duplications can lead to increased gene expression. In dosage sensitive developmental 
steps, such as gonadal differentiation, that may have detrimental phenotypic effects. 
Duplications, that due to a positional effect cause functional gene loss, can affect the 
phenotype in the same manner as a LOF mutation.  
Other chromosomal rearrangements such as translocations can cause haploinsufficiency 
by gene disruption at breakpoints. However, translocations can also render loss or gain 
of genetic material, causing a functional gain or loss of gene copies.  
In gonadal DSD all the mentioned mechanisms of disease have been described. As a 
further complication, the phenotypic effect of a mutation in DSD is dependent on the 
chromosomal sex. A loss of a gene will only affect the development of the gonadal 
form it is necessary for, and a gain will only affect the development of the gonad type 
in which it is normally down regulated. By extension, mutations that cause gonadal 
DSD can be transmitted trough healthy carriers of the opposite chromosomal sex. There 
are however also genes that are necessary for the development of both gonadal forms, 
where a phenotypic effect will be seen in both sexes. In addition, penetrance can vary 
between individuals.  
A proposed schematic overview of known and candidate genes in sex determination 
and gonadal development is given in figure 2 at the end of the introduction section. 
Genes in 46,XY gonadal DSD  
The understanding of the genetic mechanisms of 46,XY gonadal DSD took a great step 
forward in 1990 with the identification of the SRY (Sex determining region Y) gene 
[33]. SRY mutations/deletions account for approximately 10-15% of all cases of 46,XY 
GD [34] (table 3a). 
LOF mutations of WT1 (Wilms tumor 1) cause different forms of renal and gonadal 
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Table 3a. Genes in 46,XY gonadal DSD. 
Gene Locus Function 46,XY   Comment 
OMIM no  
 
Inheritance 
Gonadal 
phenotype External genitalia  
ARX 
300382 
Xp21.3 TF X-linked GD Ambiguous X-linked lissencephaly, epilepsy. 
ATRX 
300032 
Xq21.1 Helicase X-linked GD Female / 
ambiguous / male 
Associated mental retardation 
and X-linked thalassemia. 
CBX2 
602770 
17q25.3 TR AR Ovarian Female Trans-activates NR5A1 
DHH 
605423 
12q13.1 SF AD/AR GD Ambiguous Associated minifascicular 
neuropathy.  
DMRT1 
602424 
9p24.3 TF Del9p24.3 
(reduced 
penetrance) 
GD Female/ 
ambiguous 
Associated mental retardation 
depending on extent of gene 
deletion. 
GATA4 
600576 
8p.23.1-
p22 
TF AD GD / testis Ambiguous Interacts with ZFPM2,  NR5A1 
and the AMH promotor. 
ASD, VSD, atrial fibrillation.  
MAP3K1 
600982 
5q11.2 SF AD GD partial or 
complete / testis 
Female 
/ambiguous 
/hypospadia 
- 
NR0B1 
300473 
Xp21.3 NR TF? DupXp21.2 GD  Female 
Depends on dup 
extent 
LOF mutations causes adrenal 
defects in males with an X-
linked inheritance. 
NR5A1 
184757 
9q33 NR  AR/AD GD partial or 
complete / 
anorchia  
Female 
/ambiguous 
/hypospadia 
Mutations also seen in isolated 
spermatogenic failure.  
Associated with adrenal failure. 
SOX9 
608160 
17q24.3 TF AD GD / ovotestis Female / 
ambiguous 
Upregulated by SRY and 
NR5A1. 
(See table 3b) 
SRY 
480000 
Yp11.3 TF Y GD / ovotestis Female / 
ambiguous 
10-15% of XY GD. 
TSPYL1 
604714 
6q22.1 SF AR/AD GD / 
azoospermia 
Female / male SIDDT 
ZFPM2 
603693 
8q23.1 TF 46,XY,t(8;10) Hypotrophic 
testes 
Male LOF mutations , heart defects 
nteracts with GATA proteins. 
WNT4 
603490 
1p36.23-
p35 
SF Dup1p35 GD Ambiguous Associated mental retardation. 
(See table 3b) 
WT-1 
607102 
11p13 TF AD GD Female / 
ambiguous 
Wilms tumor, renal defects, 
WAGR, Denys-Drash and 
Frasier syndrome. 
TF, transcription factor; GD, gonadal dysgenesis; TR, transcriptional regulator; AR, autosomal recessive; SF, 
signaling factor; AD, autosomal dominant; Del, deletion; AMH, anti Müllerian hormone; NR, nuclear receptor; Dup, 
duplication; LOF, loss of function; WAGR, Wilms tumor, aniridia, genitourinary anomalies and mental retardation 
syndrome.  
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defects depending on mutation. Mutations can also cause the renal cancer form Wilms 
tumor. A wide range of gonadal defects in 46,XY is reported in heterozygous WT1 
mutations, from complete GD to partial forms, and also ovotesticular DSD, caused by 
haploinsufficiency. DHH (Desert Hedgehog) is necessary for NR5A1 upregulation of 
Leydig cells. Several patients with complete or partial 46,XY GD due to mutations in 
this gene are reported, both with autosomal dominant and recessive inheritance. 
Homozygous mutations of TSPYL1 (TSPY-like 1) cause sudden infant death with 
dysgenesis of the testes syndrome (SIDDT, MIM 608800) and heterozygous mutations 
are described in both GD and isolated azoospermia [35].  
Mutations in MAP3K1 (mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin 
protein ligase) cause autosomal dominant complete or partial 46,XY GD. Mutations of 
the two interacting genes GATA4 (GATA-binding protein 4) and ZFPM2 (zinc finger 
protein, FOG family member 2), formerly known as FOG2 (friend of GATA2) cause 
autosomal dominant gonadal DSD in addition to several different types of heart 
anomalies.  
Copy number changes affecting NR0B1 (Nuclear  receptor subfamily 0, group B, 
member 1) and DMRT1 (Doublesex- and MAB3-related transcription factor 1) can 
cause GD, either in isolated form, or with associated features depending on the extent 
of the duplication/deletion. Also WNT4 duplication causes 46,XY gonadal DSD with 
ambiguous genitalia. 
Mutations in several genes cause syndromic forms of 46,XY gonadal DSD. For 
instance, campomelic dysplasia (CD), a skeletal malformation, is caused by loss of 
SOX9 (SRY-box 9) due to LOF mutations, gene deletion or genetic rearrangements 
affecting regulatory regions. Patients with CD without GD are reported, and vice versa. 
Mutations in ARX (aristaless related homeobox, X-linked) and ATRX (alpha 
thalassemia/mental retardation syndrome X linked) cause X-linked 46,XY GD with 
associated symptoms. 
Genes in 46,XX gonadal DSD 
Ovarian development is dependent on RSPO1 (R-spondin family, member 1) and 
WNT4 (Wingless-type MMTV Integration site family, member 4) (table 3b). LOF 
mutations of RSPO1 cause autosomal recessive 46,XX testicular DSD with associated 
cutaneous symptoms. Also ovotesticular DSD with palmoplantar keratoderma has been 
found in one patient [36]. 
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Table 3b. Genes in 46,XX gonadal DSD. 
Gene Locus Function 46,XX   Comment 
OMIM no  
 
Inheritance 
Gondal 
phenotype External genitali  
HSD17B4 
601860 
5q23.1 Enzyme AR Ovarian 
dysgenesis 
Female Perrault syndrome with 
sensineural deafness. 
17-β-estradiol dehydrogenase IV 
MAMLD1 
300120 
Xq28 TF AD  Ovarian 
dysgenesis 
Clitoromegaly GOF mutation identified in one 
patient. 
Mutations cause hypospadia in 
46,XY.  
RSPO1 
609595 
1p34.3 SF AR Ovotestis Ambiguous Palmoplantar hyperkeratosis. 
Associated with congenital 
corneal opacities, 
onychodystrophy and hearing 
impairment. 
SOX3 
313430 
Xq27.1 TF Del/DupXq27.1 Testis Male Altered gene regulation by 
disruption of promotor region. 
SOX9 
608160 
17q24.3 TF Dup17q24 Testis, 
azoospermia 
Male (See table 3a) 
SOX10 
602229 
22q13.1 TF Dup22q13 Testis / 
ovotestis 
Male, hypospadia / 
ambiguous 
LOF mutation cases 
Waardenburg-Shah syndrome. 
SRY 
430000 
Yp11.3 TF Translocation Testis / 
ovotestis 
Male / ambiguous (See table 3a) 
WNT4 
603490 
1p36.23-
p35 
SF AD Ovary/ovotestis, 
ectopic ovary 
Variable Müllerian 
duct abnormalities. 
SERKAL, AR 
AR, autosomal recessive; TF, transcription factor; AD, autosomal dominant; GOF, gain of function; SF, 
signaling factor; Del, deletion; Dup, duplication; LOF, loss of function, SERKAL, 46,XX sex reversal 
with dysgenesis of kidneys, adrenals and lungs 
 
WNT4 mutations cause variable forms of 46,XX gonadal DSD with variable Müllerian 
duct abnormalities due to excess AMH production. Homozygous mutations of WNT4 
have been described in the SERKAL syndrome (Female to male Sex Reversal and 
Kidney, Adrenal and Lung dysgenesis). WNT4 and RSPO1 are believed to initiate 
ovarian development by stabilization of β-catenin (CTNNB1), so far only seen in mouse 
models, but it is shown that patients with SERKAL exhibit downregulated WNT4 
dependent inhibition of β-catenin degradation [37]. Another syndromic form of 46,XX 
gonadal DSD is autosomal recessive Perrault syndrome, described earlier, caused by 
mutations in HSD17B4 (17-beta-hydroxysteroid dehydrogenase IV). 
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One patient is described with a homozygous gain of function (GOF) mutation affecting 
the MAMLD1 gene, otherwise known to cause DSD in 46,XY. The patient, 46,XX 
presented with clitoromegaly, primary amenorrhea and one streak gonad with 
surrounding persistent Wolffian ducts. The other gonad was absent. Uterus and bilateral 
fallopian tubes were present [38].  
46,XX SRY positive patients, due to SRY gene translocations, can present with testicular 
or ovotesticular DSD. Also, copy number changes affecting whole genes, or gene 
regulatory elements of the SRY-box genes SOX3, SOX9 and SOX10 cause 46,XX 
testicular DSD and/or ovotesticular DSD.  
NR5A1 
The steroid production inducing transcription factor NR5A1 (Nuclear receptor 
subfamily 5, group A, member 1), previously called SF-1 (Steroidogenic factor 1), is 
important for both male and female sex development. NR5A1 is expressed in the 
developing embryo in the urogenital ridge and bipotential gonad, before SRY onset in 
46,XY. In male sex determination, NR5A1 is important for SOX9 up-regulation 
together with SRY. After the transient SRY expression has subsided, SOX9 expression 
is maintained by NR5A1 and a SOX9 feed-back loop. 
Post sex determination, NR5A1 regulates several genes in steroid synthesis such as 
CYP11A1 and CYP21A2, and is expressed in all primary steroidogenic tissues including 
adrenal cortex, Leydig cells, and ovarian theca and granulosa cells. AMH and INHA are 
regulated by NR5A1. NR5A1 expression is regulated by a promotor region E-box and is 
activated by the MAPK (mitogen-activated protein kinase) pathway.  
Due to its wide function, mutations of NR5A1 can affect different stages of gonadal 
differentiation and function, as well as cause adrenal failure. The described spectrum of 
DSD reported varies from 46,XY complete GD to mild testicular dysgenesis or 
spermatogenic failure. External genitalia can present with hypospadias, ambiguous 
genitalia, or female with clitoromegaly. Both point mutations and partial or complete 
gene deletions have been described, with either autosomal dominant or recessive 
inheritance. In addition, NR5A1 mutations have been reported in patients with POI, 
both PA and SA.  
CBX2 
The possible impact of CBX2 (Chromobox homolog 2) in human gonadal development 
was highlighted by Biason-Lauber et al reporting a patient with 46,XY ovarian DSD 
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compound heterozygous for two CBX2 mutations [21]. Mice models had previously 
shown male-to-female sex reversal in XY Cbx2
-/-
 knock out (KO) mice, despite an 
intact Sry gene [39]. Gonadal phenotype varied, ranging from ovaries with follicles, 
indistinct gonads or both testicular and ovarian tissue. Furthermore, XX Cbx2
-/-
 mice 
exhibited gonadal defects, such as smaller ovaries and/or the absence of an ovary, as 
well as structural damage of oocytes, suggesting a role for CBX2 also in ovarian 
development and maintenance, in parallel to NR5A1 mutations, first only seen in 
46,XY. 
Candidate genes in gonadal DSD 
Based on findings in mice models, there are several proposed candidate genes for 
gonadal DSD, summarized in table 4. Human phenotypic counterparts have not yet 
been described, and in some cases not identified despite larger studies. The investigated 
models are often complete KO mice, but in humans haploinsufficiency could be 
enough to cause a phenotype, as for NR5A1 mutations causing autosomal dominant 
gonadal DSD. Nr5a1 null mice exhibit gonadal and renal defects, while 
haploinsufficient mice present with isolated renal defects. The Emx2 deficient mice also 
display combined renal and genital defects, while the +/- mice are fertile.  
Interestingly, the kinase Map3k4 causes XY sex reversal in both -/- and +/- mice. It is 
shown to be essential for Sry expression, which makes it an interesting candidate gene 
for investigation in human 46,XY gonadal DSD. Also Fgf9, Fgfr2 and Lhx9 are 
interesting candidate genes, but so far human mutations have not been found despite 
several studies. Fgf9 deficiency presents with multiple system defects in mice and 
could perhaps be more suitable for investigation in patients with syndromic DSD.  
ZGLP1 is an interesting candidate for both 46,XX gonadal DSD and POI as the mouse 
model exhibits early blocked germ cell development and that the gene is normally 
expressed in granulosa cells. The two genes BAX and DDX4 (table 6) are interesting 
candidates genes for POI, but are mentioned here as XY KO mice also exhibit 
phenotypic changes. Bax deficient mice present with male infertility and disturbed 
seminiferous structures, Ddx4 deficient males are infertile.  
Most likely, there are unknown genes involved, as well as possible unknown regulatory 
or synergistic effects between known genes.  
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Table 4. Candidate genes for gonadal DSD. 
Gene Locus Function Mouse model  Human phenotype Comment 
OMIM no (Human)  XY XX XY XX  
EMX2 
600035 
10q26.11 TF -/- mutants lack 
gonads, genital tract, 
kidneys and ureters. 
- Mutations found in 
endometrial carcinoma. 
Heterozygous 
mutations in 
schizencephaly. 
- 
FGF9 
600921 
13q11-q12 GF Sex reversal / 
testicular hypoplasia. 
Lethal lung 
hypoplasia. 
- 46,XY GD patients 
investigated, no 
mutation found. 
- Role in angiogenesis and 
tumorigenesis suggested. 
Represses Wnt4 stabilization of β-
catenin in XY. 
FGFR2 
176943 
10q26 GFR Testis/ovotestis. Postnatal Fgfr2 
deletion cause 
subfertility and 
infertility.  
Crouzon, Pfeiffer, Apert, Jackson-White, Beare-
Stevenson cutis gyrata, Saethre-Chotzen 
syndrome, Craniosynostosis. 
Receptor of Fgf9. 
Independent of Sox9 and Ptgds. 
LHX9 
606066 
1q31.3 TF -/- mutants lack gonads, normal female 
phenotype. Nr5a1 expression minimal. 
46,XY GD patients 
investigated, no 
mutation found. 
- Binds to Nr5a1 promotor. Additive 
effect together with Wt-1 in Nr5a1 
activation. 
MAP3K4 
602425 
6q26 Kinase -/- both +/- sex 
reversal.  
  Somatic mutations in 
endometrial tumors. 
Map3K4 deficiency disrupt Sry 
expression.  
PTGDS 
176803 
9q34.3 Enzyme Paracrine signal for 
induction of Sertoli 
cell differentiation. 
Expression in XX 
gonads in culture 
causes male 
development. 
- - Upregulated by Sox9. 
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SOX8 
605923 
16p13.3 TF -/- gross normal 
phenotype, subfertile. 
-/+ normal fertility. 
-/- mutants 
reproductively normal. 
- - Associated alpha-
thalassemia/mental retardation 
syndrome. 
Reinforces Sox9.  
Binds and activates Amh together 
with Nr5a1. 
ZGLP1 
611639 
19p13.2 TF Defective sperm 
development.  
Expressed in Leydig 
cells. 
Blocked germ cell 
development at E17.5. 
Expressed in granulosa 
cells. 
- - Transcriptional repressor of Gata6. 
TF, transcription factor; GF, growth factor; GD, gonadal dysgenesis; GFR, growth factor receptor; WD, Wolffian ducts; KO, Knock-out 
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POI  
POI is a very heterogeneous condition and several genes as well as chromosomal 
aberrations have been shown to be associated to POI, discussed below. As for gonadal 
DSD, mutations and genomic imbalances can cause POI, both in an autosomal 
recessive, and autosomal dominant manner. An older study suggests a predominantly 
autosomal recessive pattern in POI [40].  
The ovarian differentiation and follicle organization is a complex process with 
interaction between cell lines, and is dependent on transcription factors and paracrine 
signals. Genes causing POI can affect any of these steps, also in a synergistic manner. 
The first genes causing POI identified were by analysis of translocation breakpoints and 
terminal X chromosome deletions. A summary of known and candidate genes in POI is 
given in table 5 and 6, respectively. 
Chromosomal aberrations 
The most common genetic causes of POI are chromosomal aberrations. Turner 
syndrome is the most frequent, and is diagnosed by a karyotype performed on 
lymphocytes from peripheral blood samples. Turner syndrome can be either complete 
(45,X) or present in different mosaic forms, alternatively involve a structurally 
abnormal X-chromosome [41].  
When an X chromosome is lost in one cell during embryogenesis, all daughter cells 
will be affected, creating a second cell population. Depending on when this occurs, the 
patient can be mosaic only in certain tissues. Therefore, it is important that when 
gonadal biopsies are taken, also tissue samples are analyzed for mosaicism, despite a 
normal karyotype in peripheral blood. 
Other chromosomal aberrations, such as translocations and deletions involving the X 
chromosome, account for approximately 5-10% of all cases with POI [42].  
FMR1 premutation 
The FMR1 (fragile X mental retardation 1) gene contains a trinucleotide repeat (CGG) 
that when expanded (>200) causes Fragile X mental retardation. The normal interval is 
approximately 5-44 repeats, and expansions of between 55-200 repeats are defined as 
premutations. The premutation have a potential repeat instability upon transmission. 
Therefore, in oocytes from a woman carrying a premutation, there is a high risk for 
repeat number expansion to a full mutation, causing mental retardation in the offspring. 
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The premutation carriers do not have symptom of mental retardation but are at risk to 
develop fragile X-associated tremor/ataxia syndrome (FXTAS) and/or POI [43].  
Premutations of the FMR1 gene are considered responsible for 2-5% of sporadic cases 
with POI presenting with SA [24, 44]. Conversely, premutation carriers have a high 
POI incidence of 15-20% [43, 44].  
It is not known through which mechanism the expanded FMR1 gene causes POI. It has 
been shown that mRNA levels are increased in premutations carriers, with a 
simultaneous lowered protein level, suggesting an inefficient translation with mRNA 
accumulation [45]. The FMR1 gene is expressed in both oocytes and granulosa cells 
[31], particularly during fetal life where accumulation of elongated mRNA could 
possibly damage the germ cells. Oocyte depletion has been seen in premutation carriers 
[46]. 
Diagnosed patients with POI and FMR1 expansion must be offered genetic counseling 
as they are at risk of having children with Fragile-X. In addition, close relatives should 
be offered investigation as there can be asymptomatic premutation carriers in the family 
at risk for POI or having children of their own with Fragile X.  
Transcription factors 
The oocyte specific transcription factors FIGLA (Folliculogenesis specific basic helix-
loop-helix) and NOBOX (Nobox oogenesis homeobox) are necessary for normal 
folliculogenesis (table 5). They are expressed in primordial and growing oocytes and 
were first described in mouse models. Nobox null female mice exhibit atrophic ovaries 
and are infertile, with decreased expression of the oocyte specific genes Pou5f1 and 
Gdf9. 
Figla is important in activation of genes in oogenesis, and also for repression of genes 
required for spermatogenesis in female mice. Male Figla KO mice are in turn infertile, 
too. In humans, both FIGLA and NOBOX mutations have been identified in several 
patients with POI, with suggested autosomal dominant inheritance [47, 48].  
Mutations in the granulosa cell expressed transcription factor FOXL2 (forkhead box 
L2) cause POI as an associated symptom in the BPES syndrome, mentioned earlier. 
Larger studies have investigated FOXL2 in isolated POI, but no causative mutation has 
yet been found [49].  
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Table 5. Genes in POI. 
Gene 
OMIM no 
Locus Function Inheritance Phenotype Comment 
BMP15 
300247 
Xp11.2 GF X-linked, 
dominant 
POI with PA and SA. Forms heterodimers with GDF9. 
Previously termed GDF9B. 
Expressed by oocytes in primary 
follicles. 
FIGLA 
608697 
2p13.3 TF AD POI with SA. Expressed in all follicular stages. 
FMR1 
309550 
Xq27.3 Unknown CGG repeat POI with SA. Premutation status (55-200 CGG 
repeats) associated with risk of 
POI. 
FOXL2 
605597 
3q23 TF AD POI with SA. BPES type 1. 
Upgregulated in male Dmrt1 -/- 
mice. 
FSHR 
136435 
2p21-p16 HR AR POI with PA and SA. FSHR is not expressed in 
primordial follicles.  
GDF9 
601918 
5q31.1 GF AD POI with SA, PCOS. See BMP15. Implicated in 
dizygotic twinning. 
NOBOX 
610934 
7q35 TF AD POI with SA. Transactivates GDF9 promotor. 
NR5A1 
184757 
9q33.3 NR AR/AD POI with PA and SA. Also in gonadal DSD,  
see table 3. 
PSMC3IP 
608665 
17q21.2 Several AR POI with PA. Described in one 
consanguineous family with 
several affected members. 
GF, Growth factor; POI, primary ovarian insufficiency; PA, Primary amenorrhea; SA, secondary 
amenorrhea; TF, transcription factor; AD, autosomal dominant; BPES, Blepharophimosis, ptosis, and 
epicanthus inversus syndrome; HR, hormone receptor; AR, autosomal recessive; PCOS, polycystic ovary 
syndrome ;NR, nuclear receptor; DSD, disorders of sex development 
 
 
Oocyte secreted factors 
Both BMP15 (Bone morphogenetic protein 15) and GDF9 (Growth differentiation 
factor 9) are members of the transforming growth factor beta super family (TGFB1). 
They are synthesized as prepropeptides and after processing become dimeric proteins. 
The expression of GDF9 and BMP15 is almost identical and exclusive to expression in 
follicles from primordial stage up until ovulation, and it is suggested that they form 
heterodimers. Heterozygous mutations in BMP15 and GDF9 have been described in 
patients with POI [50, 51].  
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Receptors 
The FSHR (Follicle stimulating hormone receptor) gene is located on chromosome 
2p16.3, close to the LH receptor gene. FSHR is expressed from the primary follicle 
stage with an increased expression with follicular development. Mutations in the FSHR 
gene has been described, first in Finnish families with POI, and later mutations have 
been described in other populations. Variants in the FSHR gene have also been found in 
patients with spontaneous ovarian hyperstimulation syndrome (OHSS) [52].  
Mutations in the nuclear receptor NR5A1 are associated with POI in several reports, 
with variable reported frequency between studies. So far more than 40 human 
mutations have been described. Functional studies of several mutations show impaired 
transcriptional activation of target genes [53, 54], which highlights NR5A1’s 
importance in gonad development and function.  
PSMC3IP  
Recently the PSMC3IP (PSMC3 interacting protein) gene was proposed as a novel 
gene in POI with an autosomal recessive inheritance [55]. A consanguineous family 
with several affected members with PA was described, where a homozygous 3bp 
deletion (c.600_602del, p.Glu201del) segregated with the phenotype. The mutant 
PSMC3IP protein showed a significantly decreased function as an estrogen co-
activator, possibly affecting prenatal development of the follicle pool. Estrogen is also 
important in the second stage of follicular development at puberty and PSMC3IP 
mutations could therefore possibly cause POI, with either PA or SA. 
Candidate genes in POI 
There are many proposed candidate genes in POI, an overview is provided in table 6. 
The majority have been identified in mouse models, some through genome wide 
association studies (GWAS).  
Two counteracting genes, BAX, inducing apoptosis, and BCL2 opposing apoptosis 
induction, were recently suggested as candidate genes for POI. In mouse KO models, a 
decreased follicle number has been seen, but for BAX two contradictory studies are 
reported. One study describes atrophic ovaries, and the other an increased follicle 
number. In the latter study however the aged mice were infertile, suggesting a possible 
follicle depletion. Immunohistochemical analysis of human ovarian samples shows 
expression of both genes in developing follicles. Both BAX and BCL2 should be 
investigated further in POI.  
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Table 6. Candidate genes for POI. 
Gene 
OMIM no 
Locus 
(Human) 
Function Female mouse model Human phenotype 
investigated 
Association  Comment 
BAX 
600040 
19q13.33 Induces 
apoptosis 
-/- atretic follicles with excess granulosa 
cells. 
-/- ovaries with 3-fold increase in follicle 
number but infertility in aged mice. 
Human infant/prepubertal 
ovarian samples. 
Expression in all stages of 
folliculogenesis. 
Associated with cancer. 
Acts on mitochondria to induce apoptosis. 
BCL2 
151430 
18q21.33 Resists 
apoptosis 
-/- decreased number of follicles. 
Deficiency lethal. 
Human infant/prepubertal 
ovarian samples. 
Expression in oogonia at 
gestational week 12-18 
before primordial follicle 
stage. 
Possible counteraction to BAX. 
Causes B-cell lymphoma. 
BRSK1 
609235 
19q13.42 Kinase -/- mice normal. 
Double KO model including Brsk2 lethal. 
POI and natural 
menopause. 
SNP association to POI and 
age at natural menopause. 
  
CTNNB1 
116806 
3p22.1 Junctions  Stabilization of β-catenin in XY mice cause 
male-to female sex reversal.  
- Associated with ovarian and 
endometrial cancers. 
Also called β-catenin. 
Regulated by Rspo1 and Wnt4. 
DAZL 
601486 
3p24.3 RNA binding -/- Complete female germ cell loss.  Men with spermatogenic 
failure. 
Heterozygous mutation, 
rare.. 
 
DDX4 
605281 
5q11.2 RNA helicase -/- male infertility, normal female fertility. Human infant/prepubertal 
ovarian samples. 
Selective expression in 
primordial germ cells. 
Not expressed in adult ovary. 
DIAPH2 
300108 
X21.33 Cytosolic Cause sterility in D.melanogaster. POI with SA, familial. Translocations identified in 
POI. 
 
DLX5 and 
DLX6 
600028 
and 
600030 
7q21.3 TF Double KO mice premature follicle 
maturation and reduction in follicles of all 
stages. 
 Mutation in DLX5 associated 
with AR Split-hand/foot 
malformation and hearing 
loss. 
Indication that Dlx5 inhibits Foxl2 expression, that 
in turn upregulates Foxl2 and Dlx5/6 expression. 
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ESR1 
133430 
6q25.1 TF -/- mice infertile in single Ers1a and Ers1b 
KO. 
Double KO mice exhibit testicular 
phenotype in gonads 
POI and women after 
menopause . 
Patient with estrogen 
resistance. 
SNP association to POI and 
age at natural menopause. 
LOF mutation identified. 
Estrogen receptor alpha (ER-α). 
Infertile male mice, grossly normal reproductive 
tract. 
FOXO1A 
136533 
13q14.11 TF  Foxo1a regulator of G1/S transition in 
granulosa cells 
POI with SA. Synonymous changes 
identified, not specific for 
patients. 
Associated with longevity. 
FOXO3A 
602681 
6q21 TF Early depletion of follicles and secondary 
infertility after global follicular activation. 
POI with SA. Heterozygous mutations 
identified, not POI specific. 
Evolutionary conserved direct β-catenin interaction. 
Translocations associated with leukemia. 
FST 
136470 
5q11.2 GF Upregulated in early follicle organization - - Gdf9 suppresses and Foxl2 upregulates expression. 
GATA4 
600576 
See also 
table 3a 
8p23.1 TF Expressed in granulosa and theca cells in 
preantral and antral follicles 
Regulates StAR Cyp19a1 and Inha.  
Expressed in granulosa 
and theca cells in primary 
to antral follicles, not in 
primordial. 
Mutations seen in patients 
with congenital heart 
defects. 
Regulated by Zfpm2 and Fsh. 
Suggested to protect granulose cells from apoptosis 
in mice model. 
GPR3 
600241 
1p36.11 Receptor Premature oocytes maturation, subfertility 
after superovulation. 
POI with SA No mutations found in two 
reports. 
  
HK3 
142570  
5q35.2 Kinase - POI and women after 
menopause. 
SNP association. Involved in glucose metabolism. 
INHA 
147380 
2q35 SF -/- infertile, increased FSH levels. 
Gonadal and adrenal tumors  
POI with PA and SA. SNP association. 
AR and AD POI reported, 
contradictory results. 
Inhibin (INHA-INHB) inhibits pituitary FSH 
secretion. 
Activin (INHB-INHB) stimulates secretion. 
LAMC1 
150290 
1q35 Laminin - POI with SA. SNP association study. Small sample. 
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Table 6. Candidate genes for POI, continued. 
Gene 
OMIM no 
Locus 
(Human) 
Function Female mouse model Human phenotype 
investigated 
Association  Comment 
LHCGR 
152790 
2å16.3 Receptor Indirect LH effect on follicle ovulation 
demonstrated.  
POI with PA and SA. 
 
Variable symptoms, 
oligoamenorrhea and 
infertility. 
LH receptor. 
LOF Leydig cell hyperplasia in XY. 
GOF male-limited precocious puberty in XY.  
LHX8 
604425 
1p31.1 TF -/- lack germ cells. Identical to Sohlh1 KO 
mice. 
POI with SA. No association found.  
NR5A2 
604453 
1q32.1 TF -/- lethal. 
Binds promotors for Inha, Cyp19, Hsd3b2 
and Star. 
- - Expression is dowregulated in TAF4B deficient 
mice.  
NR6A1 
602778 
9q33.3 TF -/- oocyte upregulated Bmp15 and Gdf9, 
dose dependent hypofertility. 
 
-  Represses Pou5f1 in somatic cells.  
Expressed in primary to preovulatory follicles and 
preimplantation embryos. 
PDPK1, 
RPS6 
605213, 
108460 
16p13.3, 
9p22.1 
Kinase and 
ribosomal 
protein 
-/- depletion of primordial follicles, POI in 
early adulthood. 
  Oocyte signaling in conjunction.  
PGRMC1 
300435 
Xq24 Receptor - POI with SA. Translocation and 
heterozygous mutation in 
POI. 
Mediates progesterone anti-apoptotic effect in 
ovarian cells.  
POF1B 
300603 
Xq21.1-
q21.2 
Binds actin 
filaments 
- POI with SA. R329Q mutation in AR POI 
family. 
Escapes X inactivation. 
Believed important in cell division and or apoptosis. 
POU5F1 
(OCT4) 
164177 
6p21.33 TF  -/-premature apoptosis of primordial 
follicles. 
POI with SA. No association found. Expressed in germ cells in early fetal life. 
Important in stem cells.  
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PTEN 
601728 
10q23.31 Phosphatase Premature activation and depletion of 
primordial follicle pool. 
POI with SA. No association found. Associated with cancer.  
Deficiency is lethal. 
SOHLH1 
601224 
9q34.3 TF -/- mice infertile, lack germ cells, decreased 
Figla, Nobox and Lhx8 expression. 
+/- mice normal. 
Infertile men. Mutations in men associated 
with nonobstructive 
azoospermia. 
Abundant expression in ovary after E15.5. 
Specific expression in ovary and testis. 
TAF4B 
601689 
18q11.22 RNA 
Polymerase II 
subunit 
-/- infertile, disturbed folliculogenesis. 
Decreased expression of Inhb, Inha, 
Hsd17b1, Fst and cyclin D.  
POI with SA. Suggested association in 
genome wide association 
study. 
Preferentially expressed in gonads in oocytes and 
granulosa cells. 
Mediates FSH stimulation in porcine model. 
TGFBR3 
600742 
1p33-p32 GFR Binds inhibin and increases sensitivity to 
inhibin.   
POI with SA. SNP association study, 
missense variants described. 
 
Gest, gestational; KO, Knock-out; POI, primary ovarian insufficiency; SA, secondary amenorrhea; TF, transcription factor; AR, autosomal recessive; SNP, single nucleotide 
polymorphism; LOF, loss of function; GF, Growth factor; FSH, follicle stimulating hormone; SF, signaling factor; AD, autosomal dominant; PA, primary amenorrhea; LH: 
luteinizing hormone; GOF, gain of function; GFR, growth factor receptor. 
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Novel candidate genes that have not yet been investigated in patient samples are the 
transcription factors ZGLP1 (table 4) SOHLH1, NR6A1 and the genes DAZL, FST, 
PDPK1 and RPS6, all with interesting mouse models.  
Nr5a2 deficiency is lethal, and Nr5a2 activates expression of several important genes 
in follicular maturation. NR5A2 expression is possibly regulated by TAF4B as Taf4b 
KO mice have a decreased Nr5a2 expression. Taf4b encodes a subunit of the RNA 
polymerase II and KO mice have a disturbed folliculogenesis, and a decreased 
expression of several factors in follicule function. A GWAS study has recently shown a 
suggestive association for TAF4B to POI in humans and should it be evaluated further 
[56]. The same study also suggests ADAMTS19 as a candidate gene, but the association 
could not be replicated in an independent material and no mouse model exists for this 
gene.  
Other genes identified in association studies are LAMC1 and inhibin alpha (INHA). An 
Inha KO mouse model exists with infertile mice with elevated FSH levels, but in 
humans, the association to POI is not yet proven and results are contradictory [57]. The 
receptor TGFBR3 binds inhibin and increases cell sensitivity to inhibin, suggesting a 
potential role in hormonal signaling. Four studies of TGFBR3 in POI are reported, three 
describing missense variants [58-60], but so far no functional study has been 
performed.  
The luteinizing hormone (LHCGR) and estrogen receptor 1 (ESR1) are interesting 
candidates for POI given the role of the LH and estrogen in ovulation and follicle 
maturation. However, identified mutations in LHCGR cause variable menstrual 
irregularities with normal FSH levels [61]. A patient with estrogen insensitivity and a 
ESR1 LOF mutation is described, presenting with PA but with normal FSH levels [62]. 
One GWAS study however proposes an association between a single single nucleotide 
polymorphism (SNP) in ESR1 and POI, as well as between SNPs in the genes BRSK1 
and HK3 and POI [63]. Unlike ERS1 and BRSK1, HK3 has no supporting mouse model 
and must be considered a less likely candidate despite a statistically significant 
association.  
An early investigation of translocation breakpoints identified a disruption of the 
DIAPH2 gene in a mother and daughter with POI. However, mutations in this gene 
have not been found in other POI patients. 
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The POF1B gene was also described early, with autosomal recessive (AR) POI in a 
Lebanese mother and daughter. No other patients with POF1B mutations have been 
reported.  
The transcription factors LHX8, POU5F1, FOXO1A, FOXO3A and the genes PTEN 
and GPR3 have been investigated in patients with POI without identification of any 
patient specific sequence variant. Neither is any CTNNB1/β-catenin mutation or 
association reported in POI so far. 
A proposed schematic overview for sex determination and signaling in gonad 
development, including candidate genes from mouse models, is given in figure 2. 
 
Figure 2. Proposed model including candidate genes. 
 
 
Names in italics symbolize genes. Names in smaller normal font represent protein, either enzyme or 
hormone. Names surrounded by black box represent transmembrane receptors. Cell type specific 
expression is indicated by circle. Positive interaction is indicated by arrow, negative by T-sign. Positive 
interaction involving hormones is indicated by dashed line.  
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Tilting the balance 
The mechanism how the expression of the sexually dimorphic genes control sex 
determination and maintain it is not completely understood. However, data suggest an 
important role for β-catenin in this process. Murine studies have shown that Rspo1 
induces β-catenin signaling in the developing ovary, and that when stabilized maintains 
the tissue fate [8]. In fact, expression of a stable form of β-catenin will activate the 
WNT pathway in XY gonads [64]. The β-catenin expression is inhibited in the male 
pathway, possibly through MAP3K1. This as mutations of MAP3K1 have been shown 
to cause increased β-catenin expression in a human teratoma celline expressing testis 
determination genes. Simultaneously, SOX9 was down regulated [65]. The expression 
of β-catenin is however not responsible for this down-regulation of SOX9, although a 
loss of Wnt4 or Rspo1 causes partial sex reversal in XX mice. Instead, FOXL2 has been 
proposed to be the counteracting force of SOX9. Also, loss of Foxl2 expression will 
cause mature supporting cells of the ovary to develop into testicular somatic cell types 
[66]. This suggests that the sexually dimorphic expression patterns need to be 
maintained even after sex determination, and all trough adult life. In addition, the genes 
involved in sex determination are not expressed completely in an on/off fashion 
depending on gonadal fate, but can be important in both. For instance, Rspo1/WNT/ β-
catenin expression is found in spermatogenesis [67] and Dhh signaling occurs in 
ovaries [68]. 
Aims 
29 
AIMS 
 
The overall aim of this thesis was to identify and study candidate genes in gonadal 
DSD and POI. This was done in order to achieve a better understanding of the 
underlying molecular mechanisms, and to improve the available diagnostic tools and 
genetic counseling available for affected patients and family members.  
 
The specific aims of the thesis were 
 To identify new candidate genes necessary for normal testicular development 
by investigating submicroscopic genomic imbalances in patients with 46,XY 
gonadal dysgenesis. 
 To screen for mutations in the CBX2 gene as a cause of 46,XY and 46,XX 
gonadal DSD and POI. 
 To identify new candidate genes necessary for ovarian development and or 
maintenance, by studying submicroscopic genomic imbalances in patients with 
idiopathic POI. 
 To sequence the PSMC3IP, FIGLA, NOBOX and GDF9 genes to evaluate the 
impact of mutations in these genes in a cohort of Swedish patients with POI. 
 To develop new diagnostic tools and clinical genetic investigation guidelines 
based on findings from the project.
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MATERIAL AND METHODS 
PATIENTS 
Patients were recruited among the patients referred to the Department of Clinical 
Genetics at Karolinska University Hospital, Stockholm, Sweden. The majority of 
patients are under clinical care at the Department of Obstetrics and Gynecology at the 
Karolinska University Hospital. All participants gave informed consent. In the case of 
minors, consent was obtained from legal guardians. The study was approved by the 
regional Ethics Committee at Karolinska Institutet, Stockholm, Sweden with approval 
numbers 2007/263-31/2 and 2011/276-32.  
The patients participating in this study can be divided into the following groups based on 
the clinical diagnosis. 
 Patients with 46,XY complete GD 
Women with a 46,XY karyotype, unambiguous female external genitalia and 
uterus were investigated to identify novel candidate genes in testicular 
development (paper I) and for mutations in the CBX2 gene (paper II). 
 Patients with POI 
Women with PA, early SA and familial cases have been of particular focus. The 
patient cohort was investigated for novel candidate genes causing POI by array-
CGH (paper III), and for specific gene mutations (paper II and IV). 
 Patients with other forms of gonadal DSD 
Patients with 46,XY ovotesticular DSD, 46,XX testicular or ovotesticular DSD 
and one 46,XX patient with one streak gonad and one normal functioning ovary, 
were included in the investigation of the CBX2 gene (paper II). 
 
The types of patient samples used in the studies were 
 Genomic DNA 
extracted from peripheral blood lymphocytes, EBV-immortalized lymphocytes 
and mixed tissue from gonadal biopsies. 
 RNA 
extracted from EBV-immortalized lymphocytes, and fibroblasts cultured from 
gonadal biopsies. 
Material and methods 
 31 
Clinical characterization 
The clinical characterization of patients is based on phenotype, hormonal profile and 
karyotype. In addition, family history is investigated. For patients with POI, external 
causes such as surgery, radiation therapy or autoimmunity were excluded. The clinical 
characterization was performed by the patient’s gynaecologist, and the information was 
collected at the time of inclusion in the study. 
The clinical diagnosis of 46,XY gonadal dysgenesis is based on a XY karyotype, female 
external genitalia, internal Müllerian structures (uterus) and hypergonadotropic 
hypogonadism (FSH >30 IU/L). There are two pairs of affected siblings in the patient 
group. 
The diagnosis of POI is established by occurrence of PA or SA in a woman with female 
external genitalia as well as internal Müllerian structures and hypergonadotropic 
hypogonadism. In the studied group with SA, the overall median age at diagnosis was 22 
years (12-37). Several of these patients presented with amenorrhea after oral 
contraceptive use, possibly delaying the diagnosis. 
The clinical diagnosis of 46,XY and 46,XX ovotesticular DSD is based on histological 
examination of gonads, karyotype and phenotype of external and internal genitalia. The 
diagnosis of 46,XX testicular DSD is based on karyotype, phenotype of internal and 
external genitalia and hormonal profile.  
The patient with a 46,XX karyotype, one streak gonad and one normal functioning ovary 
was discovered during abdominal surgery. The patient has normal external and internal 
female genitalia and normal female hormonal profile. 
Histological examination of gonads is recommended for all patients if possible. 
Clinical genetic analysis 
Clinical genetic investigation is commenced with conventional karyotyping that can 
detect aneuploidy, structural chromosome aberrations and mosaicism. In the studied 
patients, low level sex chromosome mosaicism has been excluded using fluorescent in 
situ hybridization (FISH) on peripheral blood smears and when available on touch 
preparations from gonadal tissue. For patients with 46,XY gonadal DSD, sequencing of 
SRY, NR5A1, WT-1, SOX9 and DHH has been performed. In addition, MLPA analysis 
targeting the 9p24 region [69] and NR5A1, SRY, SOX9, WNT4, DHH, WT1, NR0B1 
among other DSD genes [70] has been performed. 
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For patients with POI, sequencing has been performed for NR5A1, BMP15, and FSHR, 
and MLPA analysis for NR5A1. In patients with SA, FMR1 gene premutations have also 
been excluded.  
CONTROLS 
In paper II, DNA samples from anonymous blood donors at the Karolinska University 
Hospital, were used as normal controls in the investigation of novel sequence variants.  
DNA from EBV-immortalized cell lines from healthy fertile men and women, were used 
as normal controls for probe validation experiments in MLPA set up (paper II and III).  
For paper III, genomic DNA from 95 women without POI was collected as control 
samples. All women were above the age of 40 at blood sample collection and had given 
birth to at least one child. Exclusion criteria for participation were previous egg donation, 
in-vitro fertilization, fertility treatment or menopause before the age of 40.  
DNA SEQUENCING 
Novel candidate genes identified by array-CGH (C2ORF80, KRTAP2-3, KRTAP2-4, 
SUPT3H, TSPYL6, paper I and III), known gene for gonadal DSD (CBX2, paper II) and 
for POI (FIGLA, GDF9, NOBOX, PSMC3IP, paper III and IV) were sequenced to 
identify possible causative mutations. All exons, exon/intron boundaries and parts of 
5’UTR and 3’ UTR were included. Primers for PCR amplification were designed using 
Primer3Input. 
PCR conditions were optimized for each amplicon. PCR fragments were separated using 
agarose gel electrophoresis to ensure correct band size, and subsequently cleaned by 
Exonuclease I and Shrimp Alkaline Phosphatase enzyme reaction (both Thermo 
Scientific) to remove unconsumed deoxyribonucleotides (dNTP) and primers.  
The sequencing reaction was performed using the BigDye terminator kit 3.1 (Applied 
Biosystems), based on Sanger methodology with fluorescent chain terminator 
dideoxynucleotides (ddNTP). Both DNA strands were sequenced using the PCR primers. 
Fragments were size separated and analyzed using an ABI 3730 XL capillary sequencer 
(Applied Biosystems). Electropherograms were analyzed, and compared to the 
corresponding reference sequence using the SeqScape version 2.5.0 software (Applied 
Biosystems). 
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REVERSE TRANSCRIPTASE-PCR 
Reverse Transcriptase-PCR (RT-PCR) was used to investigate the expression of different 
mRNA isoforms for the SUPT3H and CBX2 genes (Paper I and II) and to confirm and 
characterize a duplication within the SUPT3H gene (Paper I). 
Total RNA was extracted from EBV-transformed lymphocytes and gonadal fibroblasts 
using the RNeasy kit (QIAGEN) including the DNAse digestion step. First strand 
synthesis, the conversion of mRNA to complementary DNA (cDNA), was performed 
using the First-Strand cDNA synthesis kit (Amersham Biosciences) and random hexamer 
primers. The DNA/RNA strand was subjected to PCR reaction using specifically 
designed primer pairs for the target of interest.  
For SUPT3H duplication analysis, a specific primer pair was designed to amplify an 
mRNA containing an interstitial duplication where exon 12 was followed by exon 5. 
PCR amplified fragments were sequenced to verify that the right fragment was amplified 
and to determine the duplication junction. 
For CBX2 expression analysis, primer pairs were designed within isoform specific exons, 
and to include at least 2 exons for ensuring isoform and cDNA specific amplification. 
ARRAY COMPARATIVE GENOMIC HYBRIDIZATION  
Array comparative genomic hybridization (array-CGH) is a technique that allows the 
detection of copy number differences between two DNA samples, of which one can be a 
chosen reference control. The array consists of a glass slide with genomic fragments 
printed on one side. We have used a customized array with one million oligomarkers. 
The oligomarkers has a genome-wide distribution, with exclusion of repetitive DNA 
sequence regions, leading to an average theoretical resolution of 2.2kb. For 78 genes 
known to be involved in gonadal development, there are additional probes to the 
backbone coverage (3 probes per exon), increasing the resolution to such extent that 
partial gene deletion or duplications can be detected (paper I and III).  
DNA quality is essential for optimal array-CGH quality control metrics (the probe to 
probe log ratio, or DLR spread). Therefore, all samples were controlled for quality, and 
purified using the QiAmp DNA minikit (QIAGEN) when appropriate to achieve 
acceptable quality values in analysis by Nanodrop 1000 spectrophotometer (260/280 1,8-
2,0, 260/230 >2). 
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Procedure 
Sample and control DNA are labeled using red (Cy5-dUTP) and green (Cy3-dUTP) 
fluorescent signals, respectively. The same amount of genomic DNA is used for both 
samples. Labeled samples are pooled together with hybridization buffer and Cot-1 DNA 
that blocks repetitive DNA sequences. The mixture is then pipetted onto a gasket slide 
that is pressed tightly against the array glass, and then placed in a rotating chamber inside 
a hybridization oven for 48h. A competitive hybridization of patient and control DNA to 
the oligomarkers on the array takes place. The array slide is then removed and washed to 
remove unhybridized material, and the fluorescent signal at each oligomarker is 
measured. Depending on the signal ratio between the red and green fluorescence, it is 
possible to determine the ratio of genomic material between the two samples. See figure 
3 for an overview of the procedure.  
Figure 3. Principles of Array-CGH. 
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In our studies we have used two commercial control samples of pooled DNA from 10 
healthy males or females. For the study with 46,XY GD patients the male reference was 
used, while the female reference was used for the study with POI patients. The same 
reference DNA batch was used throughout each study. 
Interpretation 
Fluorescence data from laser scanning was analyzed using the Cytosure interpret 
software v3.4.3 (OGT, Oxford, Great Britain). After global normalization and exclusion 
of non-uniform outliers (10% outlier removal), circular binary segmentation analysis to 
detect copy number changes was performed with a minimum consecutive probe count of 
5, a threshold for gains of 0.35 and a threshold for losses of 0.65.  
Copy number variants 
Deletions or duplications of genomic material are called copy number variants (CNV). 
The term CNV however is often used to denote the normally and frequently occurring 
copy number changes found in healthy controls, even though a CNV can represent a 
unique and causative change in one patient. International research data regarding CNVs 
in controls is collected and presented in the online Database of Genomic Variation 
(DGV). By comparing patient findings with this data, we have excluded common CNVs 
found in healthy control samples from further investigation. This exclusion was done 
with caution, as phenotypic effects of genetic imbalances affecting sexual development 
can be dependent on chromosomal sex. This information is not always available for the 
controls included in the DGV. Also, aberrations only partially overlapping with rare 
reported CNVs were not excluded. Small intronic variations and intergenic changes were 
excluded after verification that they were not located within or upstream/downstream a 
known gene causing DSD, as a positional effect could then be considered. All remaining 
novel copy number changes were confirmed by MLPA. 
Limitations 
The array-CGH method only distinguishes between ratio differences, not absolute copy 
numbers. If both control and sample carry the same number of alleles, regardless of 
number, no signal offset will be detected. The resolution of detected differences is 
dependent on type of array platform used, where number and distribution of probes vary 
between platforms. Copy number changes are also detected by SNP-array, and mixed 
arrays with both SNP and oligomarkers. 
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Positional information is not given by array-CGH. Therefore, balanced translocations 
cannot be detected as there is no change in copy numbers. In addition, detected 
duplications can theoretically be inserted anywhere in the genome. In paper I and II we 
have characterized two duplications and shown that they are placed in tandem.  
MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION 
Multiplex ligation-dependent probe amplification (MLPA) is a PCR based quantitative 
technique that allows for simultaneous detection of copy number changes of several 
target sequences in one reaction. Probes for target sequences can be placed to study 
several genes, or single exons within a gene, depending on design. The method was first 
described by Shouten et al [71] and has provided a valuable addition to the available 
cytogenetic techniques for detection of copy number changes in the size interval between 
detection by PCR and conventional cytogenetics.  
In this thesis, MLPA has been used for verification of array-CGH findings (paper I and 
III), as well as for candidate gene studies. Two MLPA probes sets using synthetic probes 
have been developed for the detection of entire and/or partial gene copy alterations of the 
CBX2 and GDF9 genes (paper II and III).  
MLPA probes  
MLPA probes are synthetic oligonucleotides designed as pairs, with a left probe oligo 
containing the forward primer sequence tag and the left hybridizing sequence, and a right 
probe oligo containing the right hybridizing sequence and the reverse primer sequence 
tag (Figure 4a). The right probe oligo has a 5’ phosphor group, essential for ligation.  
The primer sequence tags are identical in all probe oligos and allow for simultaneous 
PCR amplification of all ligated probes with only one primer pair. MLPA probe oligos 
used together in one MLPA reaction are designed to create, after ligation, fragments of 
different size. In our experiments, a minimum of 3bp in size difference has been used to 
allow for good separation in the capillary electrophoresis apparatus (ABI 3100 genetic 
analyzer, Applied Biosystems). The probes were designed according to the 
recommendations by Stern et al [72] and SNPs where avoided at least near the ligation 
site. Target specificity was controlled using the BLAT function at the UCSC genome 
browser. Probe characteristics such as GC content and melting temperature (Tm) was 
obtained using the RawProbe software. 
The probe oligo used in the MLPA probe sets for CBX2 and GDF9 analysis were 
validated for consistency by analysis of 10 healthy controls of both sexes, with a 
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standard deviation below 0.1 for each probe deemed acceptable. The control and pilot 
probe used in experiments have been described earlier [73].  
Procedure 
The synthetic oligonucleotide probe set is mixed with genomic DNA and denaturated. 
Then hybridization of left and right probe oligos to single stranded DNA is allowed for 
16h at 60ºC (Figure 4b). 
Left and right probe oligos adjacently hybridized to the DNA are ligated together at 54 
ºC to form the complete MLPA probe. Unhybridized, and unpaired probe oligos will not 
be ligated. Ligated MLPA probes are then amplified by a multiplex PCR using a 
universal primer pair. The forward primer is fluorescently labeled, allowing 
quantification during capillary electrophoresis separation of the different PCR fragments. 
The fluorescence allows for quantification of PCR productsed by measuring the area or 
height of each peak corresponding to the targeted sequence.  
Figure 4. Principles of Multiplex Ligation-dependent Probe Amplification (MLPA). 
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Controls 
For comparative quantification of copy number changes, the MLPA method is dependent 
on the use of internal reference probes. In our MLPA experiments, a minimum of at least 
three control probe pairs with stable amplification has been included in each probe set. In 
a process of internal control probe normalization, each sample’s peak height and area is 
normalized to the average peak height and area of the reference probes. The normalized 
values are then compared to the average of normalized peak height or area of control 
samples included in the run. A minimum of two appropriate control samples has been 
used in MLPA experiments.  
Interpretation 
The comparative quantification after normalization gives results in ratio values between 
sample and control. A ratio value of 1 represents equal DNA amount in the sample and 
the control for the specific target sequence of the MLPA probe. For a sample run to be 
deemed acceptable in our experiments the ratio values for the reference probes has to be 
between 0.8 and 1.2. For the target of interest a threshold value for deletion and 
duplication detection should be set. The analysis of MLPA results was initially made in 
an Excel spreadsheet and later using the GeneMarker v1.90 (Soft Genetics) software. 
Threshold values for deletions and duplications were set at 0.75 and 1.25 in Excel, and 
0.75 and 1.3 in GeneMarker, respectively. The values differ as the GeneMarker software 
uses a more complex statistical computation of the results changing the duplication cut-
off value.  
All detected deletions and duplications were verified by at least two independent MLPA 
runs and if available, a separate DNA sample from the patient was also investigated for 
confirmation.  
IN SILICO ANALYSIS, ONLINE RESOURCES AND TOOLS 
The methods used in this thesis, and the interpretation of results were dependent on 
several programs, tools and databases. For an overview including URL or manufacturer, 
see appendix II. 
As general reference source the website for the National Center for Biotechnology 
Information (NCBI) was used, including its constituent databases. In addition to 
PubMed, the database for single nucleotide Polymorphisms (dbSNP)[74] at NCBI should 
be mentioned. 
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The UCSC (University of California Santa Cruz) genome browser [75] with the 
alignment tool BLAT [76] were frequently used for all studies. Also Ensembl [77] and 
GeneCards were used frequently for general gene information. 
Software for PCR primer and MLPA probe design was used or downloaded online, 
respectively [78, 79], whereas commercial software for sequence, MLPA and array-CGH 
analysis was used. 
For interpretation of array-CGH findings the Database of Genomic Variants (DGV) v10 
released Nov 2010 [80, 81] and DECIPHER (Database of chromosomal imbalances and 
phenotype in humans using Ensembl resources) [82] were used. 
Data regarding expression patterns of genes and proteins was extracted from the general 
sources mentioned above, as well as specific online databases such as Human Protein 
Atlas [83], Database of Gene expression profiles during sex determination [84] and the 
LifeMap Database of Embryonic development, Stem Cell Research and Regenerative 
Medicine [85].  
Protein and nucleotide alignment was performed using ClustalW2 and ClustalWomega. 
Prediction of amino acid substitution on protein function was performed using the 
commercial software AlaMut and online tools Polyphen2 [86], SNP&GO and SIFT [87]. 
The prediction of nucleotide substitution on splicing efficiency was performed with 
AlaMut, as well as online tools NNSPLICEv0.9 [88], NatGene2v2.4 [89] and 
FSPLICEv1.0. 
STATISTICAL ANALYSIS 
In paper IV, binomial probability calculation is performed for estimation of statistical 
probability of negative findings. The binomial parameters were calculated using StatXact 
4 (CYTEL Software Corporation, Cambridge, USA). 95% confidence interval was 
calculated according to Clopper-Pearson. 
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RESULTS AND DISCUSSION 
CLINICAL ANALYSES (UNPUBLISHED DATA) 
Patients referred to the Department of Clinical Genetics at Karolinska University 
Hospital, Stockholm, Sweden, for genetic investigation of gonadal DSD and POI have 
been considered for this thesis. For these patients, the initial investigation of choice is a 
conventional karyotype. If an aberration is identified, this is often diagnostic. Further 
investigations that can be offered include:  
 46,XY gonadal DSD: Sequence analysis of SRY, NR5A1, WT-1, SOX9, DHH 
and MLPA analysis detecting aberrations in NR0B1, SOX9, SRY, WNT4 and 
NR5A1. 
 46,XX gonadal DSD: Sequence analysis of SRY and NR5A1. MLPA analysis 
can be considered depending on clinical presentation. 
 POI: Sequence analysis of BMP15, FSHR and NR5A1. FMR1 analysis in SA. 
Some patients have received a molecular diagnosis by routine clinical genetic 
investigation or in previous research studies. An overview is given in table 8. The 
remaining patients have been included in the studies in this thesis.  
XY gonadal DSD 
Three patients with 46,XY GD have been diagnosed with SRY point mutations, and one 
patient has a diagnostic SRY deletion. One patient has a missense mutation in the WT-1 
gene considered causative. Also different forms of chromosomal mosaicism have been 
found in three patients. For the remaining 14 patients with GD, clinical genetic 
investigations have not revealed any causative mutation. Among the three patients with 
other gonadal DSD forms, one patient with mixed GD has a causative dicentric Y-
chromosome rearrangement.  
Previous research studies in the group using BAC array and MLPA analysis, have 
identified a pair of affected siblings carrying NR0B1 duplications [90], detected before 
the development of the MLPA set now used at the Department of Clinical Genetics. 
Also one patient with a causative 9p deletion has been identified [69].  
The overall diagnostic rate in 46,XY GD can be estimated to 44% in our material. 
Previous reports vary between 20-50% [15].  
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Table 8. Results of clinical genetic investigations. 
Clinical diagnosis Patients 
studied (n) 
Total 
(n) 
Genetic 
diagnosis (n)  
Diagnosis 
established (%) 
46,XY complete GD 14 25 SRY mutation/deletion (4) 
WT1 mutation (1) 
45,X/46,XY (2) 
45,X/47,XYY (1) 
NR0B1 duplication (2) 
Del9p (1) 
44% 
46,XY gonadal DSD 
(other forms) 
2 3 45,X/46,X,idic(Y) (1) 33% 
46,XX gonadal DSD 3 4 SRY positive (1) 25% 
POI with PA 23 24 46,XX, t(X;14) (1) 4% 
POI with SA 31 35 FMR1 premutation (1) 
46,XX,del(X) (2) 
46,XX, t(X;4) (1) 
11% 
GD, gonadal dysgenesis; Del, deletion; DSD, disorders of sex development; POI, primary ovarian 
insufficiency; PA, primary amenorrhea; SA, secondary amenorrhea. 
 
 
XX gonadal DSD 
One patient with 46,XX testicular DSD has been diagnosed as SRY positive, explaining 
the phenotype. The remaining patient with 46,XX testicular DSD, 46,XX ovotesticular 
DSD and the patient with one streak gonad and one functioning ovary, have not 
received a molecular diagnosis. 
POI 
Four patients with POI had diagnostic aberrant karyotype with either X-chromosome 
deletion or translocations involving the X-chromosome. One had PA and three had SA. 
In three patients, balanced translocations involving autosomes have been identified, but 
not considered causative. One of these patients has participated in the studies included 
in this thesis. The remaining two patients have not been available for inclusion.  
One patient with SA has been diagnosed with a causative FMR1 premutation. This 
corresponds to a detection rate of 1/54=2.8% which is expected for unrelated cases (2-
5% in previous reports) [24, 44].  
In total, 54 patients with POI were included in the study, 23 with PA and 31 with SA. 
All patients with POI participating in the studies of this thesis have undergone sequence 
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analysis of the BMP15, FSHR and NR5A1 genes. No causative mutation has been 
identified, although three novel changes have been found.  
One patient is a heterozygous carrier of a novel silent change in the BMP15 gene 
(c.393T>C), inherited from the mother. A novel silent change was found in the FSHR 
gene in another patient in heterozygous form (c.1653C>T), no parental samples were 
available. The silent changes were not predicted to affect splicing.  
In NR5A1 a missense change was identified in one patient with SA, c.771C>G, 
p.Asp257Glu. The patient is heterozygous, and the mother does not carry the change. 
Paternal samples were not available. The amino acid substitution occurs in a nuclear 
hormone receptor ligand binding domain, but the substitution is, based on prediction 
tools and the similarity between exchanged amino acids, considered benign.  
These patients are included in study II, III and IV of this thesis. 
Conclusion 
The diagnostic rate is higher for the group with 46,XY gonadal DSD than for 46,XX 
gonadal DSD and POI. This can be due to differences in mutation frequency of 
causative genes in 46,XY and 46,XX respectively, reflect that POI is a more 
heterogeneous condition, or illustrate that the group with 46,XX gonadal DSD and POI 
is far less studied than 46,XY.  
Through previous research in the group studying 46,XY GD, three patients could 
receive a molecular diagnosis. This was the rationale to extend the study to also include 
46,XX patients and to further analyze the undiagnosed 46,XY patients in the current 
project.  
A karyotype is always necessary for the analysis of patients with gonadal DSD and POI 
as it is the basis of classification of DSD forms, and can also be diagnostic alone, such 
as in the case of mosaicism or translocations involving the X chromosome. For patients 
with SA, FMR1 analysis must be recommended, especially in familial cases. It is a 
simple and affordable analysis, and there can be undetected younger carriers in the 
family at risk for POI. In addition, premutation carriers have an increased risk of having 
children with Fragile-X mental retardation, and must be offered genetic counseling.  
Today, there are several known genes in gonadal DSD and POI to investigate in 
patients. A suitable genetic investigation must be recommended for giving affected 
patients a molecular diagnosis. Even if not influencing therapy recommendations, a 
molecular diagnosis will provide the patient with an explanation, which can be some 
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consolation in a difficult condition. A summary of the clinically relevant genes as of 
today is given in the concluding remarks.  
 
GENOME WIDE APPROACH TO IDENTIFY NOVEL CANDIDATE 
REGIONS IN 46,XY GONADAL DYSGENESIS (PAPER I)  
Attempting to identify new potential candidate regions involved in testicular 
development, we have investigated patients with complete 46,XY GD for 
submicroscopic genetic imbalances using a genome wide approach. The process of sex 
determination is sensitive to gene dosage, both to haploinsufficiency and gene 
duplication, and genes affecting gonadal development are located not only on the sex 
chromosomes but also on autosomes.  
DNA samples from nine unrelated patients with 46,XY GD, of which one also has an 
affected 46,XY sister, were analyzed by array-CGH. A 1 M array-CGH platform with 
2.2 kb probe spacing for whole genome coverage and enrichment targeting 78 genes 
involved in gonadal development was used.  
Four of the nine analyzed patients had novel copy number alterations, with a total of 
five rearrangements. Of these, one is a previously described benign duplication of the 
SRD5A2 gene, paternally inherited [73]. Four additional patients with 46,XY GD and 
one with ovotesticular DSD were included in follow-up studies of novel regions. The 
four most interesting candidate genes identified in the study are discussed below. 
SUPT3H on 6p21.1 
A duplication within the SUPT3H gene (suppressor of Ty 3 homologue S. cerevisiae) 
and a deletion affecting the C2ORF80 gene, discussed in the next paragraph, were 
detected in the affected pair of siblings. Both changes are inherited from the healthy 
mother. It is possible that one of these changes is a benign variant, or that the causative 
mechanism is by an interacting or additive effect. However, at the moment no common 
pathways are known between SUPT3H and C2ORF80. 
The duplication within the SUPT3H gene was further characterized by MLPA and RT-
PCR, and shown to be an interstitial tandem duplication of exon 5 through 12, placing 
exons in the order 1-12 followed by 5-13 (figure 5). The duplication affects both major 
isoforms of SUPT3H and causes a likely C terminal amino acid change. The SUPT3H 
protein is well conserved in mammals and it is difficult to predict if a terminal change 
affects protein function or stability. SUPT3H expression is high in testicular cells  
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Figure 5. SUPT3H duplication.  
 
A, SUPT3H gene, exon organization. Green exons are not present in mRNA variant 1. Exon 5 and exon 
12 have been colored in blue and yellow respectively, to help to understand the duplication structure,; B, 
SUPT3H mRNA variants. The exons in gray are not coding. ATG indicates the initiation of translation.; 
C, Duplication structure. 
 
 
(Leydig, interstitial and germ cells), and seminiferous ducts. It is a transcriptional co-
activator [91] and the human homolog of the yeast transcription factor Spt3 in which 
mutations cause defects in mating and sporulation [92]. 
C2ORF80 on 2q34 
The deletion of the C2ORF80 gene (chromosome 2 open reading frame 80) spans the 
first eight of a total of nine exons, thus removing one allele. The gene is poorly 
characterized. C2ORF80 is moderately expressed in testicular cell types (Leydig cells 
and cells in seminiferous ducts) and ovarian stroma cells, among others. The protein 
does not contain any known functional domain, and does not present homology with 
any known protein. It is highly conserved in other species down to frog and fish, with a 
47% sequence homology with D.rerio.  
We investigated all available patients with 46,XY gonadal DSD by sequence analysis, 
to detect inactivating mutations of SUPT3H and C2ORF80, although none were found. 
Due to the small group size this negative results must be interpreted with caution, and 
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we consider both SUPT3H and C2ORF80 as interesting candidate genes for 46,XY 
GD. 
PIP5K1B and PRKACG on 9q21.11 
An unrelated patient carried a 454 kb duplication within 9q21.11, possibly affecting 
two interesting candidate genes, PIP5K1B and PRKACG.  
The duplication spans the last four exons of the PIP5K1B (Phosphatidylinositol-4-
Phosphate 5-kinase, Type1, Beta) gene. Positional data cannot be inferred by array-
CGH and it is possible the patient has two normal alleles. The duplication can also 
disrupt one allele.  
The PIP5K1B gene is highly conserved in the mammalian clade, and has a 67% 
sequence homology with D.rerio. The PIP5K1B enzyme function is not completely 
understood, but it is an active signaling molecule involved in cytoskeleton 
reorganization, cell survival, epithelial cell morphogenesis and more [93].  
Mouse Pip5Ka (corresponding to human PIP5K1B) has a very high expression in testis 
and in germ, Sertoli, and Leydig cells [93]. Pip5Ka and Pip5Kb (corresponding to 
human PIP5K1A) double deficient mice are completely sterile due to lack of germ 
cells. Pip5Ka KO mice are subfertile due to reduced motility and abnormal morphology 
of sperm. Based on these findings, the potential role for PIP5K1B in human gonadal 
development must be further evaluated. 
The PRKACG gene (homo sapiens protein kinase, cAMP-dependent, catalytic, gamma) 
encodes the gamma form of the catalytic subunit of cAMP-dependent kinase, a 
retrotransposon derived from the alpha form. In contrast to the widely expressed alpha 
and beta forms, the gamma form is highly tissue-specific to human testis, and germ 
cells in particular [94]. We consider PRKACG an interesting candidate gene for XY 
GD.  
Conclusion 
By array-CGH we have identified novel candidate genes in 46,XY GD. Proving 
causality for identified variants is challenging and experimental functional 
characterizations should ideally be undertaken. The identification of recurrent or related 
genetic variants in other groups of patients with well documented phenotypes could 
also provide support for the potential role of these genes in gonadal DSD.  
All studied patients had undergone MLPA analysis for detection of dosage imbalances 
in several known gonadal DSD genes [69, 73, 95]. Therefore it was not surprising that 
Results and discussion 
46  
no such rearrangements were detected here. However, array-CGH is a powerful 
technique with high potential resolution, capable of detecting diagnostic genomic 
imbalances, as well as novel candidate genes, and we recommend that all patients with 
46,XY GD without a molecular diagnosis should undergo copy number change 
analysis. 
 
CBX2 CANDIDATE GENE STUDY (PAPER II) 
The purpose of this study was to investigate the presence of point mutations and gene 
copy number changes in the CBX2 gene in a group of patients with gonadal DSD. One 
reported patient, compound heterozygous for CBX2 mutations and with 46,XY ovarian 
DSD highlighted the potential role for CBX2 in human gonadal development. In murine 
models, Cbx2 KO mice exhibit XY and XX gonadal disturbances, including germ cell 
instability in XX gonads. Therefore we proposed CBX2 as a candidate gene for 46,XY 
and 46,XX gonadal DSD, as well as for POI. A cohort of 47 patients with different 
gonadal DSD forms or POI were included in the study. We used DNA sequencing and 
an in-house developed MLPA probe set for specific identification of 
deletions/duplications affecting CBX2. 
Sequence alterations 
10 changes, nine single nucleotide variations and one insertion were identified. Nine 
are reported SNPs. A novel silent G to A transition (c.1356G>A) was identified in 
heterozygous form in a patient with POI and PA, maternally inherited. Both alleles 
were expressed in gonadal fibroblast cultured from the patient. No effect on splicing 
could be predicted by three different splice site prediction tools. The nucleotide change 
was not identified in 156 control alleles, however we believe it is a rare normal variant. 
Its maternal inheritance in the patient argues further against a pathogenic role in POI 
when in heterozygous form. 
All patients were found to carry the G allele for SNP rs71368052 (c.-52C>G) in the 
CBX2 promotor. This is likely an annotation error as the available data from two 
population studies in dbSNP reveals only G allele carriers. 
A non synonymous SNP, p.Pro471Ala was identified in a patient with PA, inherited 
from the healthy father. Both alleles were expressed in gonadal fibroblasts from the 
patient, excluding a second mutation affecting gene expression. Pro471 is conserved in 
eutherian mammals (figure 6). It is not in one of the highly conserved domains of CBX 
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proteins [96, 97], but it is the first amino acid after the conserved CBX2-specific motif 
Cx2.2 [97], making it difficult to predict a specific functional role. It is reported as a  
Figure 6. CBX2 amino acid conservation.  
 
Partial alignment of the CBX2 protein. Pro471 and corresponding residues in other species is highlighted 
in yellow. Blue and green show part of the functionally important Cx2.2 and Pc box, respectively, in 
human CBX2. Consensus symbols are indicated considering only mammalian (nine top) or all species 
proteins. An * (asterisk) indicates positions with a fully conserved residue; a : (colon) indicates 
conservation with residues of strongly similar properties; a . (period) indicates conservation with residues 
of weakly similar properties.  
 
 
very rare SNP and was not detected in 156 control alleles in our study. Causative 
mutations for rare recessive diseases are expected to be listed as very rare SNPs as there 
will be healthy heterozygous carriers in the population. It cannot be excluded that the 
nucleotide variant constitutes a potentially causative mutation. However, in the reported 
patient, CBX2 mutations caused autosomal recessive disease, affecting a 46,XY 
subject. Therefore it is less likely that a heterozygous change inherited from a 46,XY 
father would be causative alone in the 46,XX patient, in whom we have also confirmed 
expression of both two alleles. 
Copy number changes 
No deletion or duplication affecting the CBX2 gene was detected in the patient cohort 
by MLPA. These results are surprising to us as four copy number variants involving 
CBX2 are registered in the CNV database. Three variants are reported encompassing 
the entire gene detected at a reported frequency of one loss in 39 controls, one loss in 
269 and two gains and one loss in 30. In addition, a change spanning exon 1 to 3 is also 
described with one loss and 22 gains out of 50 controls by de Smith et al. Due to the 
reported high frequency of CNVs, we expected to find some patients with a 
heterozygous deletion, or partial gene duplication. The reported high frequency by de 
Smith et al in a French population not replicated in our experiments could constitute a 
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population difference, or it could also represent a false positive array-CGH result in the 
previous study.  
Expression 
The CBX2 gene is reported to be transcribed in two isoforms, but no expression pattern 
has been reported. Therefore, we investigated the expression of the two CBX2 isoforms 
in two cell lines and have successfully shown that both RNA isoforms are expressed in 
gonadal fibroblasts as well as in EBV-immortalized lymphocytes. It still remains to be 
determined if isoform 2 is translated into a protein. 
Conclusion 
Despite the potential importance of CBX2 in human sex development our study on a 
group of 46,XX and 46,XY gonadal DSD cases did not reveal any causative point 
mutations in the CBX2 gene. Neither was any gene deletion or duplication detected by 
MLPA. Consequently, our study does not support CBX2 gene mutations as a common 
cause of gonadal DSD.  
 
GENOME WIDE APPROACH TO IDENTIFY NOVEL CANDIDATE 
REGIONS IN PRIMARY OVARIAN INSUFFICIENCY (PAPER III) 
The aim of this study was to identify novel candidate genes for ovarian development 
and function by investigating submicroscopic genetic imbalances in patients with POI. 
By a genome wide approach, novel candidate genes could be identified both on the X 
chromosome and on autosomes. DNA samples from 26 patients with POI were 
analyzed by array-CGH using the same platform as described for Paper I.  
11 unique copy number changes were identified in a total of 13 patients. One aberration 
affects the GDF9 gene, already associated to POI, the other ten changes unravel novel 
candidate regions. All aberrations were confirmed by MLPA. When possible, 
inheritance pattern was investigated. Maternally inherited changes have not 
automatically been excluded as a variable phenotype expression due to polygenic or 
environmental factors, or an autosomal recessive inheritance cannot be excluded.  
An MLPA probe set for identification of copy number changes in the novel candidate 
regions identified by array-CGH was developed. This was used for investigation of 95 
controls, and an additional 28 patients with POI. The extended cohort and control 
material were also used in the follow-up studies of candidate genes. Below, the 
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identified duplication affecting the GDF9 gene, and six candidate genes for POI are 
discussed.  
GDF9 on 5q31.1 
A partial duplication within the GDF9 (Growth differentiation Factor 9) gene was 
identified in a patient who had SA at 15 years of age. Using PCR, we amplified the 
duplication junction (figure 7) and could by sequencing confirm a tandem, head to tail 
duplication, of 475bp containing the first part of the 5’ UTR and a short upstream DNA 
sequence. 
Figure 7. GDF9 duplication. 
 
 
A. Schematic representation of the GDF9 gene. ATG indicates the initiation of translation. Red dots 
represent NOBOX binding elements (NBE). Purple dot represents the E-box. Yellow arrow indicates the 
duplicated segment. Blue arrows represent PCR primers for duplication breakpoint amplification. R, 
reverse primer; F, forward primer. B. Schematic representation of the duplication. Blue arrows represent 
PCR primers. Green line represents PCR product containing duplication junction. C. Representation from 
the UCSC genome browser, GRCh37/hg19 assembly. Horizontal yellow arrow line indicates the 
duplicated segment. Location of NBE (TAATTA, TAATTG) and E-box (CAGCTG) are shown as 
vertical red and purple lines, respectively. Vertical black boxes represent MLPA probes.  
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GDF9 is an oocyte secreted factor, expressed from the primary follicle stage, and is 
necessary for normal folliculogenesis and fertility. Mutations of GDF9 are associated 
with POI, although at a low frequency [51, 98-100].  
Within the duplicated region there are three NOBOX binding elements (NBE), and an 
E-box sequence. In mouse, NBEs regulate Gdf9 expression and the E-box sequence is 
necessary for the ovarian specific expression of Gdf9. Both the NBEs and the E-box are 
conserved between mouse and human, as well as several other species and are likely 
important for regulation of human GDF9 expression. The identified duplication is 
likely to have caused an altered GDF9 expression in the patient’s ovary, leading to POI. 
This is the first mutation identified affecting the regulatory region of GDF9. 
As a further investigation, the entire patient cohort (total 54 patients) was investigated 
by an in-house designed MLPA probe set, for the identification of 
deletions/duplications within or encompassing GDF9. No additional case was found. 
DNAH6 on 2p11.2  
A 171kb deletion affecting the DNAH6 (Dynein axonemal heavy chain 6) was 
identified in one patient with SA at 22 years of age. Another array-CGH study has 
described a smaller, partially overlapping deletion detected in a patient with SA (figure 
8) [101]. An additional study has also identified the related DNAH5 as a candidate gene 
for POI [102]. Mutations in DNAH5 are otherwise known to cause primary ciliary 
dyskinesia (PCD). 
DNAH6 is a heavy axonemal dynein chain. Dyneins are microtubule-associated motor 
protein complexes, which are important for ciliary and flagellar motility. Also, dyneins 
have been suggested to have a role in ovarian development. In adult tissues DNAH6 
can be found in fallopian tubes and testis, among other tissue types. We believe that 
DNAH6 is a very interesting candidate gene for POI. 
Figure 8. DNAH6 deletion. 
 
Representation from the UCSC genome browser, GRCh37/hg19 assembly. The green line represents the 
deletion detected in Patient 21. The orange line show the deletion reported by Ledig et al. Vertical black 
lines represent MLPA probes. 
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TSPYL6 on 2p16.2 
A deletion affecting the TSPYL6 gene (TSPY-Like 6 ) was identified in a patient with 
PA. The TSPYL6 gene function is unknown, but it has a C-terminal NAP (nucleosome 
assembly protein) domain, where NAP proteins are known to affect gene transcription 
by histone moving and nucleosome assembly. Homozygous mutations of TSPYL1 have 
been found to cause 46,XY gonadal dysgenesis and sudden infant death syndrome 
(SIDDT). We consider TSPYL6 an interesting candidate gene for POI. As a further 
investigation, we sequenced the TSPYL6 gene in the entire patient cohort. No 
inactivating mutations were identified. 
SMARCC1 and CSPG5 on 3p21.31 
A 135kb duplication on chromosome 3p21.31 was found in a patient with PA. The 
duplication spans the SMARCC1 gene (SWI/SNF related matrix associated actin 
dependent regulator of chromatin subfamily c member1) and at least the first two exons 
of the CSPG5 gene (chondroitin sulfate proteoglycan 5). SMARCC1 regulates 
transcription by chromatin remodeling and is highly expressed in both follicle and 
ovarian stroma cells, among other cell types in various tissues. CSPG5 is a 
proteoglycan that may function as a differentiation factor. In mice, there is a differential 
expression profile of Cspg5 in Sf1+ somatic cells in developing gonads at embryonic 
day 12.5 (E12.5) with a higher expression in male gonads, and with an increasing 
expression in female gonads on E13.5. 
We consider both SMARCC1 and CSPG5 possible candidate genes for POI.  
SH3GL3 on 15q25.2  
A duplication of almost the entire sequence of the first intron of the SH3GL3 gene 
(SH3-domain GRB2-like 3) was identified in a patient with PA. The SH3GL3 gene 
contains a SRC Homology-3 (SH3) domain involved in signal transduction for 
transcriptional regulation. SH3GL3 expression is abundant in testis where it is believed 
important for spermatogenesis. It is moderately expressed in follicle cells. 
By array-CGH no positional data can be obtained. An interstitial duplication could 
affect splicing or have no effect. An association between SH3GL3 and POI should be 
further investigated.  
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Del 19p13.3 
A 128kb deletion on chromosome 19 was identified in a patient with SA affecting 6 
genes: TJP3, APBA3, MRPL54, RAX2, MATK, and ZFR2. Of these, the ZFR2 gene 
(zinc finger RNA binding protein 2) is an interesting candidate gene for POI. Its 
function is not fully understood, but it can bind double stranded RNA or RNA/DNA 
hybrids. ZFR2 is expressed in many adult cell types, including ovarian follicle and 
stroma cells. It addition, ZFR2 is expressed in female gametocytes and germ cells 
during embryonic development. Ovarian biopsies from the patient shows bilateral 
complete lack of oocytes and follicles.  
KRTAP2-3 and KRTAP2-4 on 17q21.2 
Three patients with SA were found to carry a 9kb deletion encompassing the KRTAP2-
3 (Keratin associated protein 2-3) and KRTAP2-4 (Keratin associated protein 2-4) 
genes, two heterozygous and one homozygous for the deletion. We hypothesized an 
autosomal recessive causative mechanism and by sequencing we detected a missense 
substitution (p.Cys73Tyr) in the remaining allele of the two heterozygous patients. The 
variant is reported (rs113397060), but with no allele frequency. As the prediction 
program Polyphen2 predicted the change to be probably damaging we investigated all 
patients and the control material for this change. One patient was found to be 
homozygous for the substitution, but also one control. Therefore we do not consider 
KRTAP2-3 as a candidate gene for POI. It is possible that this deletion of KRTAP2-3 
and KRTAP2-4 is a normal variant in the Swedish population, although not reported in 
DGV, as two controls were also found to be heterozygous for the deletion. 
Conclusion 
Using array-CGH, we have identified the first mutation affecting the regulatory region 
of GDF9 in a patient with SA, most likely pathogenic. Importantly, the small, 475bp 
duplication, would not have been detected without the customized probe enrichment, 
making clear that platform resolution and probe targeting is crucial. We have also 
identified a second DNAH6 deletion in a patient with SA, corroborating DNAH6 as a 
candidate gene for POI. In addition, we have identified several novel candidate genes in 
POI. Even though descriptive in its form, studies reporting recurrent and related genetic 
variants in phenotypically well characterized groups of patients can contribute to the 
identification of novel candidate genes in gonadal development and maintenance and 
supporting the initiation of functional studies. 
Results and discussion 
  53 
PSMC3IP GENE STUDY (PAPER IV) 
The PSMC3IP (PSMC3 interacting protein) gene was implicated in POI in 2011. In a 
consanguineous family with several members with PA, all affected patients shared a 
terminal homozygous 3bp deletion (c.600_602del, p.Glu201del). The mutant protein 
showed a significantly decreased function as an estrogen co-activator. Estrogen is 
important for prenatal development of the follicle pool and follicular development at 
puberty. A decreased estrogen-dependent transcription could thereby possibly cause 
POI presenting with PA or SA. No other study has investigated the PSMC3IP gene in a 
group of unrelated patients with POI. It is of interest to investigate the possible 
frequency of pathogenic mutations in new candidate genes for POI. This is both for 
diagnostic purposes, and for strengthening the understanding of the gene function in 
ovarian development and maintenance. Therefore, we investigated a cohort of 50 
patients with POI for possible PSMC3IP mutations. 
Sequencing results 
Samples from 50 patients were successfully sequenced. No mutations or sequence 
variations in the coding region of the PSMC3IP gene were detected. In intron 4, a novel 
heterozygous change was identified in one patient with SA at 37 years of age. The 
intronic transition c.337+33A>G is not previously reported. In silico analysis of 
splicing efficiency using three different prediction tools did not support an effect of the 
variant on splicing. Although we could not detect this change in any of the 190 control 
alleles investigated we believe it constitutes a rare normal variant. 
Conclusion 
The PSMC3IP gene has so far only been investigated in a single consanguineous family 
with hereditary POI. The present study is based on a group of 50 patients with POI 
where no mutation of the PSMC3IP gene was detected. Using binomial probability 
calculation we can note that the probability of detecting mutations in zero out of fifty 
patients with POI with an assumed POI population prevalence of possible causative 
PSMC3IP mutations of 5.8%, is only 5% (exact confidence interval 0-7.11%). This is 
less than reported for mutations in the autosomal gene NOBOX in Caucasian patients 
with POI and some reported studies of FMR1 premutations. We can therefore conclude 
that PSMC3IP gene mutations are not a common cause of POI in this Swedish cohort. 
A population difference cannot be excluded, our patients are mostly Swedish 
(Caucasian), whereas the family investigated by Zangen et al was of Palestinian 
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descent. It remains possible that the described mutation can be found in a higher 
prevalence in patients of this ethnic background.  
For clinical genetic investigation of POI, a single gene approach with consecutive 
screening by conventional sequencing of candidate genes has so far been quite 
unsuccessful and expensive, with a low detection rate per gene investigated. With the 
development of next generation sequencing techniques, a multiple gene approach 
where a panel of known candidate genes is analyzed simultaneously, could be more 
successful. 
 
POI GENE SEQUENCING (UNPUBLISHED DATA) 
In addition to the clinical genetic investigation of BMP15, FSHR and NR5A1, all 
included patients with POI, in total 54 patients without a molecular diagnosis, have 
been analyzed for inactivating mutations in the GDF9, FIGLA and NOBOX genes. No 
definitive causative mutation was found, although some novel or rare changes were 
identified. The results are summarized in table 9. 
FIGLA  
Seven reported changes were identified in the cohort (table 9a). Of these, one is a very 
rare missense variant p.Pro93Thr, detected in 5 out of 4093 European American 
controls, 0 out of 1842 African American in whole-exome sequencing reports. The 
change is predicted damaging Polyphen2, Mutation taster, SIFT and Align GCVD. The 
patient carries this change in heterozygous form. We investigated our control material 
of 95 healthy women without POI and did not detect any additional carrier. Previously 
reported FIGLA mutations with a possible causative effect have been described in 
heterozygous form [47]. Unfortunately, no parental samples were available for this 
patient. If we could show that the change was either paternally inherited or de novo, its 
pathogenicity would be strengthened. It is however an interesting candidate for further 
evaluation with functional studies.  
The other detected changes are either common, likely benign or do not predict any 
potential change in splicing. 
 
Results and discussion 
  55 
GDF9 
In GDF9, five reported SNPs were identified in the cohort (table 9b), four common 
changes and one with no reported minor allele frequency (MAF). These are either silent 
changes, or outside the coding regions. Splice site prediction tools do not predict any 
change in splicing for any change.  
NOBOX 
Sequencing of the NOBOX gene revealed one novel change and twelve reported SNPs 
(table 9c). The novel change is silent (c.1548C>T) and juxtaposed a common 
polymorphism. It was not detected in any control allele, but is maternally inherited. The 
change is not predicted to introduce any splice site and is likely a rare polymorphism. 
In one patient the missense change p.Arg117Trp was detected. It has previously been 
described as potentially damaging [103], but it has a reported MAF of 1.7%, which is 
too common for a causative change in the rare condition POI. The MAF however is 
based on a sample of only 38 controls, meaning it was detected in heterozygous form in 
one control, which does not have to represent the distribution in the entire population. 
However another study reported the minor allele in 13 of 118 alleles in a control 
material, which speaks more strongly against a causative role. We did not have access 
to parental samples, and consider the variant interesting for further evaluation. The 
other changes are either common, maternally inherited, predicted benign or not 
influencing splicing.
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Table 9a. FIGLA sequencing results (unpublished data). 
SNP ID Reported MAF Nucleotide change Location Amino acid 
change 
POI 
(54) 
Study pop MAF 
rs12713717 G=0.398/869 c.231+24T>C Intron 1 - T/T:26 
T/C:23 
C/C:5 
0.31 
rs200665269 - c.277C>A  Exon 2 p.Pro93Thr C/C:53 
C/A:1 
A/A:0 
0.01 
rs7566476 C=0.249/543 c.422G>C  Exon 3 p.Ser141Thr G/G:9 
G/C:27 
C/C:17 
0.56 
rs7566541 G=0.216/472 c.552C>T Exon 3 p.His184= C/C:13 
C/T:24 
T/T:20 
0.59 
rs144711401  -=0.016/35 c.644+109_644+112delGGAA Intron 4 - GGAA/GGAA:51 
GGAA/-:3 
-/-:0 
0.03 
rs56135050 T=0.317*691 c.*5T>A 3’UTR - T/T:23 
T/A:28 
A/A:3 
0.31 
rs56316086 G=0.314/686 c.7* A>G 3’UTR - A/A:23 
A/G:28 
G/G:3 
0.31 
NM_001004311.3 is used as reference sequence.  
SNP ID, single nucleotide identification number; MAF, minor allele frequency; POI, primary ovarian insufficiency; pop, population; UTR, untranslated 
region. 
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Table 9b. GDF9 sequencing results (unpublished data) 
SNP ID Reported MAF Nucleotide change Location Amino acid 
change 
POI 
(54) 
Study pop MAF 
rs17166282   C=0.044/95 NM_005260.3:c.-32A>G 5’UTR - A/A:53 
A/G:0 
G/G:1 
0.02 
rs254285  C=0.185/402 NM_005260.3:c.398-39G>C Intron 1 - G/G:1 
G/C:6 
C/C:47 
0.91 
rs254286  A=0.454/993 c.447C>T Exon 2 p.Thr149= C/C:13 
C/T:18 
T/T:23 
0.59 
rs10491279 T=0.162/353 c.546G>A Exon 2 p.Glu182= G/G:43 
G/A:10 
A/A:1 
0.11 
rs376173165 - c.1182T>C  Exon 2 p.Tyr394= T/T:53 
T/C:1 
C/C:0 
0.01 
SNP ID, single nucleotide identification number; MAF, minor allele frequency; POI, primary ovarian insufficiency; pop, population. 
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Table 9c. NOBOX sequencing results (unpublished data). 
SNP ID MAF 
reported 
Nucleotide change Location Amino acid 
change 
POI 
(54) 
MAF 
Study pop 
Comments 
rs1208179  G=0.079/171 c.42T>C Exon 1 p.Gly14= T/T:33 
T/C:18 
C/C:2 
0.20 - 
rs727714 G=0.336/732 c.262C>T Exon 3 p.Leu88= C/C:9 
C/T:27 
T/T:17 
0.56 - 
rs7800847 T=0.017/38 c.349C>T Exon 4 p.Arg117Trp C/C:53 
C/T:1 
T/T:0 
0.01 Potentially causative. 
rs201806397 -  c.454G>A Exon 4 p.Gly152Arg G/G:51 
G/A:3 
A/A:0 
0.03 Predicted benign. 
Maternally inherited (2). 
rs373867875 - c.715C>T Exon 4 p.Arg239Trp C/C:53 
C/T:1 
T/T:0 
0.01 Predicted benign. 
rs370846754 - c.795G>A Exon 4 p.265Pro= G/G:53 
G/A:1 
A/A:0 
0.01  
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rs757388 A=0.337/733 c.1154+11T>C Intron 6 - T/T:32 
T/C:21 
C/C:11 
0.40 - 
rs11769847  C=0.336/732 c.1155-23G>A Intron 6 - G/G:11 
G/A:24 
A/A:18 
0.56 - 
rs2525702 A=0.118/257 c.1444G>A Exon 8 p.Gly482Ser G/G:34 
G/A:18 
A/A:2 
0.20 Predicted benign. 
Novel change - c.1548C>T  Exon 9 p.Pro516= C/C:53 
C/T:1 
T/T:0 
0.01 Maternally inherited (1). 
Not found in 190 control 
alleles. 
rs2699503  T=0.350/762 c.1549T>C Exon 9 p.Phe517Leu   T/T:20 
T/C:28 
C/C:16 
0.56 Common, likely tolerated. 
rs1208216  A=0.082/179 c.1796C>A Exon 10 p.Pro599His C/C:34 
C/A:18 
A/A:2 
0.20 Predicted benign. 
rs77802098  G=0.024/52 c.1991A>G Exon 10 p.Lys664Arg A/A:52 
A/G:2 
G/G:0 
0.20 Predicted benign. 
Paternally inherited (1). 
NM_001080413.3 is used as reference sequence. 
SNP ID, single nucleotide identification number; MAF, minor allele frequency; POI, primary ovarian insufficiency; pop, population; UTR, untranslated 
region. 
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CONCLUDING REMARKS - FUTURE PERSPECTIVE 
Gonadal disorders of sex development (DSD) are rare conditions affecting patients with 
46,XY or 46,XX karyotype. The gonadal phenotype can vary, and depending on the 
hormonal profile, the phenotype of internal and external genitalia can differ. Primary 
ovarian insufficiency (POI) can present as a continuous spectrum of ovarian 
dysfunction, from primary amenorrhea (PA) to secondary amenorrhea (SA). The 
overall aim of this thesis was to identify and study candidate genes in gonadal DSD and 
POI. A molecular diagnosis in these conditions can offer the patient a causative 
explanation for their condition and provide for a more specific genetic counseling of 
family members. In addition, by identifying novel genes we can also achieve a better 
understanding of the underlying molecular mechanisms of gonadal development and 
maintenance.  
By genome wide array-CGH analysis of patients with 46,XY gonadal dysgenesis we 
have identified new candidate genes for testicular development. Copy number changes 
affecting the SUPT3H and C2ORF80 genes were identified and characterized in two 
affected sisters with 46,XY GD. We also implicate the PIP5K1B and PRKACG genes 
as potential candidate genes. 
By a candidate gene approach, we have investigated the CBX2 gene for sequence 
alterations and copy number changes in a group of patients with 46,XY or 46,XY 
gonadal DSD, or POI. Our negative findings do not support CBX2 gene mutations as a 
common cause for these conditions.  
Using array-CGH we have identified the first mutation affecting the regulatory region 
of GDF9 in a patient with SA, most likely pathogenic. We have also identified a second 
patient with SA and DNAH6 deletion, corroborating the role for DNAH6 in POI and 
making it worth proceeding with functional characterization. In addition, we have also 
identified TSPYL6, SMARCC1, CSPG5, SH3GL3 and ZFR2 as candidate genes in POI. 
We have investigated the PSMC3IP, FIGLA, NOBOX and GDF9 genes for sequence 
alterations in a cohort of patients with POI. No causative mutations were found, but two 
changes to follow up were identified. In addition, we have investigated the cohort for 
copy number changes affecting GDF9 where no additional case to the patient identified 
by array-CGH was found. 
MLPA has been used to develop diagnostic tools for the identification of copy number 
changes of GDF9 and CBX2.  
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The genetic investigation of patients with gonadal DSD should always be centralized to 
a specialized DSD unit. Also, the investigation and treatment of patients with POI is 
suitable for centralization to subspecialists within reproductive endocrinology. In 
addition to the clinical investigation and substitution therapy requiring special interest 
from the physician, results from the clinical genetic investigation can have impact on 
the entire family. Genetic counseling must be offered these patients and the family 
members. A suggested clinical investigation procedure for POI is given in Appendix 1. 
Based on the current knowledge, I can recommend the following genetic investigations 
today: 
 For patients with isolated 46,XY GD: investigation of sequence alterations of SRY, 
NR5A1, WT-1, SOX9, DHH, MAP3K1, TSPYL1 and GATA4 and copy number 
change analysis of NR0B1, SOX9, SRY, WNT4, NR5A1, DMRT1. Only one patient 
has been described with mutations in CBX2 and our study has not identified any 
other mutation. Before any new supporting data is provided CBX2 analysis cannot 
be recommended as a clinical investigation. 
 For patients with POI: investigation of sequence alterations of BMP15, FIGLA, 
FSHR, GDF9, NOBOX, and NR5A1. Also FMR1 analysis is recommended in 
patients with SA. FOXL2 mutations have so far only been described in patients 
with BPES, but it is possible that mutations of this gene could present with isolated 
POI, as in acampomelic SOX9 mutations. Therefore it should be considered for 
diagnostic investigation. Mutations in PSMC3IP have so far only been described in 
one family and our study has not revealed any additional case. Until another report 
supports its importance it cannot be recommended as a clinical analysis. Copy 
number change analysis of the aforementioned genes must also be considered in 
patients with POI. Investigation of promotor regions in sequence and copy number 
change analyses should be considered.  
The knowledge of implicated genes in gonadal development is rapidly increasing and it 
is important that the genetic investigations conducted are constantly evolving, and also 
retrospectively offered patients diagnosed earlier.  
For genetic investigation of patients with gonadal DSD or POI, the simultaneous 
detection of gene dosage aberrations and small DNA sequence aberrations would be 
preferred, and ideally conducted in a validated, fast and cost-efficient manner. In the 
future, once next generation sequencing will provide reliable data on copy numbers, 
whole-genome sequencing could be considered for diagnostic purposes.  
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It would be interesting to apply next generation sequencing to identify novel candidate 
genes in gonadal DSD and POI by studying families with several affected members. 
We have now samples from another pair of sisters with 46,XY GD where we would 
like to collect DNA samples from parents and the unaffected sibling. In addition, we 
are trying to include family members of a patient with POI with PA, where several 
sisters are also affected with POI with a variable phenotype. Both these families would 
be very interesting to study further as the familial cluster strongly suggests a common 
genetic mechanism. 
However, the number of sequence alterations identified in each investigated person by 
next generation sequencing is extensive and both laborious and difficult to interpret. 
Using a family based approach, we could exclude changes that do not segregate with 
phenotype, and also perform analysis depending on an assumed dominant or recessive 
inheritance pattern. This would greatly decrease the amount of data noise in search of 
the true signal.  
Novel candidate genes identified by such an approach, as well as the rare missense 
variants identified in the FIGLA and NOBOX genes, would be interesting to investigate 
by functional studies. Also DNAH6 is a candidate gene for functional investigation. 
Animal models could be considered, but in vitro techniques and cell-based systems 
could be designed to evaluate the expression and function of mutant protein compared 
to its wild type counterparts. 
For POI, a multicentre approach with a large numbers of patients and controls could 
form the basis of association studies evaluating SNP frequency in patients compared to 
controls, in attempts to localize genes and genomic regions important for gonadal 
function. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
“Hur många barn får jag när jag blir stor?” 
När jag var barn lekte vi en lek på dagis då vi kastade en näve grus i luften medan vi sa 
”hur många barn får jag när jag blir stor?”. Antalet stenar man fångade var antalet barn 
man skulle få som vuxen. Ibland fick man tio, ibland inga, och då kunde man bara 
prova igen. Hur fånig denna lek än framstår för en vuxen, så är bristen på kontroll över 
sin fertilitet, eller snarare infertilitet, ett vanligt problem idag och ungefär 10-15% av 
alla par behöver någon form av hjälp för att bli gravida.  
Det finns många bakomliggande orsaker till infertilitet, både manliga och kvinnliga 
faktorer. Denna avhandling rör de ovanliga tillstånd där äggstockar eller testiklar, 
gemensamt kallade gonader, inte har utvecklats eller har förlorat sin funktion i förtid. 
Dessa patienter är normala flickor, förutom att de antingen inte kommer i puberteten 
eller förlorar sin mens i mycket unga år. Den drabbade kan ha en manlig 
kromosomuppsättning, 46,XY, eller kvinnlig, 46,XX, och motsvarande kliniska 
diagnos kallas 46,XY gonad dysgenesi (GD) eller primär ovariell insufficiens (POI). 
POI kan orsakas av externa faktorer såsom kirurgi, strålning, cytostatikabehandling, 
och även av autoimmunitet, men genetiska faktorer spelar en stor roll. Vi vet också att 
styrningen under fosterlivet från ett neutralt gonadanlag till utvecklingen av testikel 
eller äggstockar regleras av genetiska mekanismer.  
Genom att studera patienter med 46,XY GD och POI hoppas vi kunna få en bättre 
förståelse för de underliggande mekanismer som styr den normala gonadutvecklingen. 
Därmed hoppas vi kunna ge fler patienter en förklaring till varför just de drabbats, 
vilket kan vara en liten lättnad i ett tillstånd som det annars kan vara svårt att förlika sig 
med. En diagnos medför även att den genetiska rådgivning vi kan erbjuda patienten och 
familjen blir säkrare och bättre.  
Denna avhandling består av fyra delprojekt: 
 Identifiering av nya kandidatgener för testikelutvecklingen. Vi har använt en 
specialdesignad högupplöst platform för detektion av mycket små förluster eller 
dubblering av arvsmassa. Metoden kallas array-CGH. Med denna teknik har vi 
identifierat fyra gener som vi tror kan ha betydelse för den normala utvecklingen 
av testikeln. Generna heter SUPT3H, C2ORF80, PIP5K1B och PRKACG. Alla 
uttrycks normalt i testikeln, och förlust av Pipk51b ger sterilitet hos manliga möss 
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vilket ytterligare stöder vår hypotes. Dessa gener behöver studeras vidare för att 
bättre kunna förstå deras funktion. (Artikel I) 
 Studier av kandidatgenen CBX2. Genen Cbx2 har beskrivits påverka 
gonaduvecklingen hos möss, och en patient har beskrivits med mutationer i denna 
gen och normal äggstocksutveckling trots en manlig karyotyp. Vi undersökte 
huruvida mutationer i denna gen förekom hos våra patienter med 46,XY GD och 
POI. Inga mutationer påträffades i vår undersökta grupp och vi kan därmed sluta 
oss till att CBX2 mutationer inte är en vanlig orsak till dessa tillstånd. (Artikel II) 
 Array-CGH studier av patienter med POI. Vi har identifierat den första mutationen 
som påverkar den reglerande regionen för genen GDF9 som är essentiell för 
äggstocksutvecklingen. Dessutom har vi påvisat en andra förlust av genen DNAH6 
hos en patient med POI, vilket stärker dennas troliga roll i normal 
äggstocksutveckling och funktion. Vi beskriver även nya kandidatgener för POI, 
TSPYL6, SMARCC1, CSPG5, SH3GL3 och ZFR2. (Artikel III) 
 Studier av kandidatgenerna PSMC3IP, FIGLA och NOBOX. En mutation i genen 
PSMC3IP har beskrivits orsaka POI i en familj med flera drabbade. I vårt material 
kunde vi inte påvisa någon mutation, och därmed vet vi att mutationer i PSMC3IP 
inte är en vanlig orsak till POI i Sverige. Vi har hittat två möjligt 
sjukdomsorskande förändringar i generna FIGLA respektive NOBOX som behöver 
studeras vidare. (Artikel IV och opublicerade data) 
Sammanfattningsvis kan vi se att 46,XYGD och POI är genetiskt heterogena tillstånd. 
Kunskapen kring de mekanismer som styr utvecklingen av och funktionen i testikel och 
äggstock ökar snabbt. Den genetiska utredning som görs bör följa med i utvecklingen 
och innefatta analys av både punktmutationer av arvsmassan såväl som analys av 
förlust eller dubblering av genetiskt material.  
De drabbade patienterna bör skötas av specialister, och för POI innebär detta av 
gynekolog med subspecialisering inom reproduktiv endokrinologi. Centralisering är 
viktigt för utredning, rådgivning och behandling då patienter utan egen 
könshormonsproduktion måste få individuellt anpassad ersättning och uppföljning. 
Patienter med en manlig kromosomuppsättning löper risk att drabbas av tumörer i den 
kvarvarande testikelvävnaden, vilket kräver specialistbdömning och handläggning.  
Oavsett kromosomuppsättning kan alla patienter med 46,XYGD och POI bli mammor 
med hjälp av äggdonation, och flera av våra patienter har redan fått barn på detta sätt. 
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APPENDIX 1. SUGGESTED CLINICAL INVESTIGATION 
OF WOMEN WITH POI 
CLINICAL PRESENTATION: 
Primary amenorrhea with absent or delayed pubertal development. Infantile external 
female genitalia. (Tanner stage can vary depending on sex steroid production from 
adrenal glands) 
OR 
Secondary amenorrhea before 40 years of age in a previously menstruating woman for 
at least 4 months  
accompanied by hypergonadotropic hypogonadism 
 
BASIC INVESTIGATION  
Clinical / gynecological examination. 
Ultrasonography or magnetic resonance imaging for investigation of presence of 
internal female genitalia.  
Hormonal profile: FSH, LH, estradiol, testosterone, TSH, T4, prolactin 
Genetic investigation: Karyotype 
Gonadal biopsies should be taken if laparoscopy is performed, and correct sample 
handling must be ensured before surgery.  
 
Patients with a 46,XY karyotype should be referred to a DSD specialist.  
Patients with a normal 46,XX karyotype should be referred to a gynecological 
specialist in reproductive endocrinology.  
Patients with 46,XY or 46,XX chromosomal DSD should be referred for clinical 
genetic counseling. The clinical care is recommended to be handled by a DSD 
specialist.  
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SPECIALIST INVESTIGATION  
The following investigations are recommended to be handled by, or performed in 
collaboration with, a subspecialist within reproductive endocrinology.  
Immunological profile: autoantibodies against cytochrome P450scc, 17α hydroxylase, 
21 hydroxylase and TPO. In the case of positive findings, an extended analysis of 
autoantibodies against transglutaminase, parietal cells, GAD, IA2 and TRAK, is 
suggested. 
Genetic investigation: FMR1 premutation analysis in secondary amenorrhea. Gene 
sequencing and copy number analysis in collaboration with clinical genetic laboratory. 
 
GONADAL BIOPSY INVESTIGATION 
Biopsy material from gonads from patients with POI should be investigated by a 
pathologist for histological examination. In addition, a biopsy should be sent for FISH 
(fluorescent in situ hybridization) analysis at a clinical genetic laboratory to exclude 
gonadal chromosomal mosaicism. It is also suggested that fibroblasts be cultured and 
saved from this material for possible future analysis.  
 
 
A flowchart for the referral of patients is given below. 
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APPENDIX II. IN SILICO ANALYSIS, PROGRAMS, RESOURCES AND TOOLS. 
Name URL / Manufacturer Comment 
NCBI http://www.ncbi.nlm.nih.gov/ Overall reference source with biomedical and genomic information.  
Used databases include PubMed, SNP, Gene, Protein, HomoloGene and OMIM 
among others. 
UCSC http://genome.ucsc.edu/ Genome browser. Use to retrieve sequences and gene information. 
BLAT tools used for primer and probe specificity control. 
Ensembl http://www.ensembl.org/ Genome browser. 
GeneCards http://www.genecards.org/ Collection of gene information. 
Primer3Input http://primer3.ut.ee/ Primer design. 
RaW-Oligov0.15β http://www.mlpa.com/WebForms/WebFormMain
.aspx?Tag=zjCZBtdOUyAt3KF3EwRZhAPz9Q
Em7akikAm7AOEGw1vtZvffaZPOiSig8uqel7Y
d 
MLPA probe design, available for download at the MRC Holland website. 
SeqScapev2.5 Applied Biosystems Sequence analysis. 
Gene Mapper Applied Biosystems MLPA analysis. 
GeneMarkerv1.90 Soft genetics MLPA analysis. 
Cytosure Interpret Software 
v3.4.3 
Oxford Gene Technology Array-CGH analysis. 
DGV http://dgv.tcag.ca/dgv/app/home CNV data. 
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DECIPHER  http://decipher.sanger.ac.uk/ CNV and phenotype data. 
The Human Protein Atlas http://www.proteinatlas.org/ Human protein expression data. 
Gene expression profiles 
during sex determination  
http://nef.unige.ch/microarrays.php Gene expression data. 
LifeMap  http://discovery.lifemapsc.com Expression data. 
ClustalW2 and ClustalW 
omega 
http://www.ebi.ac.uk/Tools/msa/clustalw2/ and 
http://www.ebi.ac.uk/Tools/msa/clustalo/ 
Nucleotide and protein alignment. 
AlaMutv2.3 Interactive Biosoftware Mutation analysis by combining Align GVGC, SIFT, MutationTaster and 
PolyPhen2. 
Splicing analysis by combining SpliceSiteFinder-like, MaxEntScan, NNsplice, 
GeneSplicer and Human Splicing finder. 
Polyphen2 http://genetics.bwh.harvard.edu/pph2/ Missense mutation analysis (protein level). 
SIFT http://sift.bii.a-star.edu.sg/ Missense mutation analysis (protein level). 
SNP&GO http://snps-and-go.biocomp.unibo.it/snps-and-go/ Missense mutation analysis (protein level). 
FSPLICEv1.0  http://linux1.softberry.com/berry.phtml?topic=fsp
lice&group=programs&subgroup=gfind 
Splice site analysis. 
NetGene2v. 2.4  http://www.cbs.dtu.dk/services/NetGene2/ Splice site analysis. 
NNSPLICEv0.9  http://www.fruitfly.org/seq_tools/splice.html Splice site analysis. 
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